Activation	O
of	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
Treponema	B-protein
pallidum	I-protein
and	I-protein
Borrelia	I-protein
burgdorferi	I-protein
lipoproteins	I-protein
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF-kappa	B-protein
B	I-protein
.	O

There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	B-protein
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O

A	O
principal	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
more	O
precisely	O
similarities	O
and	O
divergences	O
among	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
and	O
lipoprotein-lipopeptide-induced	O
immune	O
cell	O
signaling	O
events	O
.	O

Like	O
LPS	O
,	O
purified	B-protein
native	I-protein
B.	I-protein
burgdorferi	I-protein
OspA	I-protein
and	O
synthetic	O
analogs	O
of	O
OspA	B-protein
,	O
OspB	B-protein
,	O
and	O
two	O
T.	B-protein
pallidum	I-protein
lipoproteins	I-protein
(	O
Tpp47	B-protein
and	O
Tpp17	B-protein
)	O
all	O
induced	O
NF-kappa	B-protein
B	I-protein
translocation	O
in	O
THP-1	B-cell_type
human	I-cell_type
monocytoid	I-cell_type
cells	I-cell_type
.	O

Acylation	O
of	O
OspA	B-protein
and	O
the	O
synthetic	O
peptides	O
was	O
requisite	O
for	O
cell	O
activation	O
.	O

Polymyxin	O
B	O
abrogated	O
only	O
the	O
response	O
to	O
LPS	O
.	O

By	O
using	O
70Z/3-derived	B-cell_line
pre-B-cell	I-cell_line
lines	I-cell_line
either	O
lacking	O
or	O
expressing	O
human	B-protein
CD14	I-protein
(	O
the	O
LPS	B-protein
receptor	I-protein
)	O
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	B-protein
CD14	I-protein
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	O
to	O
OspA	B-protein
or	O
spirochetal	B-protein
lipopeptides	I-protein
(	O
assessed	O
by	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
expression	O
of	O
surface	B-protein
immunoglobulin	I-protein
M	I-protein
)	O
.	O

Finally	O
,	O
the	O
biological	O
relevance	O
of	O
the	O
observation	O
that	O
T.	B-protein
pallidum	I-protein
lipoproteins	I-protein
-lipopeptides	O
induce	O
both	O
NF-kappa	B-protein
B	I-protein
and	O
cytokine	B-protein
production	O
in	O
monocytes	B-cell_type
was	O
supported	O
by	O
the	O
ability	O
of	O
the	O
synthetic	O
analogs	O
to	O
promote	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
chronically	O
infected	O
U1	O
monocytoid	O
cells	O
;	O
these	O
observations	O
also	O
suggest	O
a	O
potential	O
mechanism	O
whereby	O
a	O
syphilitic	O
chancre	O
can	O
serve	O
as	O
a	O
cofactor	O
for	O
human	O
immunodeficiency	O
virus	O
transmission	O
.	O

The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	B-protein
lipoproteins	I-protein
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O

INFECTION	NULL
AND	NULL
ImmMUNITY	NULL
,	NULL
Sept.	NULL
1996	NULL
,	NULL
p.	NULL
3845-3852	NULL
0019-9567/96/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

64	NULL
,	NULL
No	NULL
.	NULL

9	NULL
Activation	NULL
of	NULL
Human	NULL
Monocytic	NULL
Cells	NULL
by	NULL
Treponema	NULL
pallidum	NULL
and	NULL
Borrelia	NULL
burgdorferi	NULL
Lipoproteins	NULL
and	NULL
Synthetic	NULL
Lipopeptides	NULL
Proceeds	NULL
via	NULL
a	NULL
Pathway	NULL
Distinct	NULL
from	NULL
That	NULL
of	NULL
Lipopolysaccharide	NULL
but	NULL
Involves	NULL
the	NULL
Transcriptional	NULL
Activator	NULL
NF-kB	NULL
MICHAEL	NULL
V.	NULL
NORGARD	NULL
,	NULL
'	NULL
LESLIE	NULL
L.	NULL
ARNDT	NULL
,	NULL
'	NULL
DARRIN	NULL
R.	NULL
AKINS	NULL
,	NULL
``	NULL
LINDA	NULL
L.	NULL
CURETTY	NULL
,	NULL
``	NULL
DAVID	NULL
A.	NULL
HARRICH	NULL
,	NULL
``	NULL
anp	NULL
JUSTIN	NULL
D.	NULL
Departments	NULL
of	NULL
Microbiology*	NULL
and	NULL
Internal	NULL
Medicine	NULL
,	NULL
``	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
Southwestern	NULL
Medical	NULL
Center	NULL
,	NULL
Dallas	NULL
,	NULL
Texas	NULL
75235	NULL
Received	NULL
19	NULL
April	NULL
1996/Returned	NULL
for	NULL
modification	NULL
15	NULL
May	NULL
1996/Accepted	NULL
25	NULL
June	NULL
1996	NULL
There	NULL
is	NULL
increasing	NULL
evidence	NULL
that	NULL
lipoproteins	NULL
of	NULL
Treponema	NULL
pallidum	NULL
and	NULL
Borrelia	NULL
burgdorferi	NULL
are	NULL
key	NULL
inflammatory	NULL
mediators	NULL
during	NULL
syphilis	NULL
and	NULL
Lyme	NULL
disease	NULL
.	NULL

A	NULL
principal	NULL
objective	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
identify	NULL
more	NULL
precisely	NULL
similarities	NULL
and	NULL
divergences	NULL
among	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
-	NULL
and	NULL
lipoprotein-lipopep-tide-induced	NULL
immune	NULL
cell	NULL
signaling	NULL
events	NULL
.	NULL

Like	NULL
LPS	NULL
,	NULL
purified	NULL
native	NULL
B.	NULL
burgdorferi	NULL
OspA	NULL
and	NULL
synthetic	NULL
analogs	NULL
of	NULL
OspA	NULL
,	NULL
OspB	NULL
,	NULL
and	NULL
two	NULL
T7	NULL
.	NULL

pallidum	NULL
lipoproteins	NULL
(	NULL
Tpp47	NULL
and	NULL
Tpp17	NULL
)	NULL
all	NULL
induced	NULL
NF-KB	NULL
translocation	NULL
in	NULL
THP-1	NULL
human	NULL
monocytoid	NULL
cells	NULL
.	NULL

Acylation	NULL
of	NULL
OspA	NULL
and	NULL
the	NULL
synthetic	NULL
peptides	NULL
was	NULL
requisite	NULL
for	NULL
cell	NULL
activation	NULL
.	NULL

Polymyxin	NULL
B	NULL
abrogated	NULL
only	NULL
the	NULL
response	NULL
to	NULL
LPS	NULL
.	NULL

By	NULL
using	NULL
70Z/3-derived	NULL
pre-B-cell	NULL
lines	NULL
either	NULL
lacking	NULL
or	NULL
expressing	NULL
human	NULL
CD14	NULL
(	NULL
the	NULL
LPS	NULL
receptor	NULL
)	NULL
,	NULL
it	NULL
was	NULL
observed	NULL
that	NULL
expression	NULL
of	NULL
human	NULL
CD14	NULL
imparted	NULL
responsiveness	NULL
to	NULL
LPS	NULL
but	NULL
not	NULL
to	NULL
OspA	NULL
or	NULL
spirochetal	NULL
lipopeptides	NULL
(	NULL
assessed	NULL
by	NULL
induction	NULL
of	NULL
NF-KB	NULL
and	NULL
expression	NULL
of	NULL
surface	NULL
immunoglobulin	NULL
M	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
biological	NULL
relevance	NULL
of	NULL
the	NULL
observation	NULL
that	NULL
T.	NULL
pallidum	NULL
lipoproteins-lipopeptides	NULL
induce	NULL
both	NULL
NF-KB	NULL
and	NULL
cytokine	NULL
production	NULL
in	NULL
monocytes	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
synthetic	NULL
analogs	NULL
to	NULL
promote	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
replication	NULL
in	NULL
chronically	NULL
infected	NULL
U1	NULL
monocytoid	NULL
cells	NULL
;	NULL
these	NULL
observations	NULL
also	NULL
suggest	NULL
a	NULL
potential	NULL
mechanism	NULL
whereby	NULL
a	NULL
syphilitic	NULL
chancre	NULL
can	NULL
serve	NULL
as	NULL
a	NULL
cofactor	NULL
for	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
transmission	NULL
.	NULL

The	NULL
combined	NULL
data	NULL
lend	NULL
additional	NULL
support	NULL
to	NULL
the	NULL
proposal	NULL
that	NULL
spirochetal	NULL
lipoproteins	NULL
and	NULL
LPS	NULL
initiate	NULL
monocyte	NULL
activation	NULL
via	NULL
different	NULL
cell	NULL
surface	NULL
events	NULL
but	NULL
that	NULL
the	NULL
signaling	NULL
pathways	NULL
ultimately	NULL
converge	NULL
to	NULL
produce	NULL
qualitatively	NULL
similar	NULL
cellular	NULL
responses	NULL
.	NULL

Syphilis	NULL
and	NULL
Lyme	NULL
disease	NULL
are	NULL
chronic	NULL
infections	NULL
caused	NULL
by	NULL
the	NULL
pathogenic	NULL
spirochetes	NULL
Treponema	NULL
pallidum	NULL
and	NULL
Borrelia	NULL
burgdorferi	NULL
,	NULL
respectively	NULL
(	NULL
35	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Although	NULL
each	NULL
is	NULL
distinctive	NULL
,	NULL
syphilis	NULL
and	NULL
Lyme	NULL
disease	NULL
share	NULL
a	NULL
number	NULL
of	NULL
clinical	NULL
features	NULL
and	NULL
are	NULL
characterized	NULL
by	NULL
similar	NULL
histopathological	NULL
findings	NULL
(	NULL
35	NULL
,	NULL
42	NULL
)	NULL
.	NULL

One	NULL
potential	NULL
explanation	NULL
for	NULL
the	NULL
similar	NULL
inflammatory	NULL
responses	NULL
induced	NULL
by	NULL
7.	NULL
pallidum	NULL
and	NULL
B.	NULL
burgdorferi	NULL
is	NULL
that	NULL
both	NULL
organisms	NULL
synthesize	NULL
abundant	NULL
lipid-modified	NULL
integral	NULL
membrane	NULL
proteins	NULL
(	NULL
10	NULL
,	NULL
11	NULL
,	NULL
56	NULL
)	NULL
.	NULL

By	NULL
analogy	NULL
with	NULL
findings	NULL
reported	NULL
for	NULL
the	NULL
murein	NULL
lipoprotein	NULL
of	NULL
Escherichia	NULL
coli	NULL
(	NULL
22	NULL
,	NULL
25	NULL
)	NULL
,	NULL
we	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
that	NULL
spirochetal	NULL
lipoproteins	NULL
are	NULL
potent	NULL
activators	NULL
of	NULL
immune	NULL
effector	NULL
cells	NULL
,	NULL
including	NULL
monocytes-mac-rophages	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
endothelial	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
14	NULL
,	NULL
36	NULL
,	NULL
37	NULL
,	NULL
43	NULL
,	NULL
50	NULL
,	NULL
51	NULL
,	NULL
53	NULL
,	NULL
58	NULL
,	NULL
63	NULL
,	NULL
71	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
,	NULL
coupled	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
neither	NULL
spirochete	NULL
contains	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
(	NULL
20	NULL
,	NULL
49	NULL
,	NULL
64	NULL
)	NULL
,	NULL
support	NULL
the	NULL
contention	NULL
that	NULL
lipoproteins	NULL
are	NULL
important	NULL
proinflammatory	NULL
molecules	NULL
of	NULL
syphilis	NULL
and	NULL
Lyme	NULL
disease	NULL
.	NULL

A	NULL
major	NULL
problem	NULL
in	NULL
studying	NULL
the	NULL
proinflammatory	NULL
properties	NULL
of	NULL
spirochetal	NULL
lipoproteins	NULL
arises	NULL
from	NULL
the	NULL
difficulty	NULL
in	NULL
obtaining	NULL
adequate	NULL
quantities	NULL
of	NULL
these	NULL
bacterial	NULL
constituents	NULL
under	NULL
endotoxin-free	NULL
conditions	NULL
.	NULL

As	NULL
an	NULL
extension	NULL
of	NULL
findings	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
Southwestern	NULL
Medical	NULL
Center	NULL
,	NULL
5323	NULL
Harry	NULL
Hines	NULL
Blvd	NULL
.	NULL

,	NULL
Dallas	NULL
,	NULL
TX	NULL
75235-9113	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
214	NULL
)	NULL
648-6896	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
214	NULL
)	NULL
648-5476	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
jradol	NULL
@	NULL
mednet.swmed	NULL
.edu	NULL
.	NULL

3845	NULL
by	NULL
Bessler	NULL
and	NULL
colleagues	NULL
(	NULL
22	NULL
,	NULL
25	NULL
)	NULL
,	NULL
we	NULL
recently	NULL
showed	NULL
that	NULL
this	NULL
problem	NULL
can	NULL
be	NULL
circumvented	NULL
through	NULL
the	NULL
use	NULL
of	NULL
synthetic	NULL
lipopeptides	NULL
corresponding	NULL
to	NULL
the	NULL
N-terminal	NULL
domains	NULL
of	NULL
spirochetal	NULL
lipoproteins	NULL
(	NULL
14	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Particularly	NULL
intriguing	NULL
were	NULL
our	NULL
findings	NULL
that	NULL
LPS	NULL
and	NULL
spirochetal	NULL
lipopeptides	NULL
elicited	NULL
qualitatively	NULL
similar	NULL
cytokine	NULL
patterns	NULL
from	NULL
human	NULL
and	NULL
murine	NULL
macrophages	NULL
even	NULL
though	NULL
they	NULL
appeared	NULL
to	NULL
utilize	NULL
distinct	NULL
signaling	NULL
pathways	NULL
(	NULL
50	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Prompted	NULL
by	NULL
the	NULL
overall	NULL
importance	NULL
of	NULL
elucidating	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
spirochetal	NULL
constituents	NULL
induce	NULL
inflammatory	NULL
processes	NULL
,	NULL
we	NULL
conducted	NULL
additional	NULL
studies	NULL
to	NULL
identify	NULL
similarities	NULL
and	NULL
divergences	NULL
among	NULL
the	NULL
LPS-	NULL
and	NULL
lipoprotein-induced	NULL
cell	NULL
signaling	NULL
pathways	NULL
.	NULL

We	NULL
found	NULL
that	NULL
both	NULL
spirochetal	NULL
lipoproteins	NULL
and	NULL
synthetic	NULL
analogs	NULL
induced	NULL
the	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
a	NULL
transcriptional	NULL
activator	NULL
heavily	NULL
implicated	NULL
in	NULL
cytokine	NULL
induction	NULL
in	NULL
monocytoid	NULL
cells	NULL
and	NULL
in	NULL
activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
gene	NULL
expression	NULL
and	NULL
replication	NULL
(	NULL
41	NULL
,	NULL
54	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
stimulation	NULL
,	NULL
NF-kB	NULL
is	NULL
present	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
com-plexed	NULL
with	NULL
the	NULL
inhibitor	NULL
protein	NULL
IxB	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Upon	NULL
appropriate	NULL
stimulation	NULL
,	NULL
an	NULL
alteration	NULL
in	NULL
IxB	NULL
allows	NULL
dissociation	NULL
of	NULL
this	NULL
complex	NULL
.	NULL

Active	NULL
NF-kB	NULL
then	NULL
translocates	NULL
into	NULL
the	NULL
nucleus	NULL
,	NULL
where	NULL
it	NULL
binds	NULL
to	NULL
its	NULL
DNA	NULL
recognition	NULL
sites	NULL
to	NULL
mediate	NULL
gene	NULL
transcription	NULL
.	NULL

Interestingly	NULL
,	NULL
lipoproteins-lipopeptides	NULL
did	NULL
not	NULL
promote	NULL
activation	NULL
and	NULL
translocation	NULL
of	NULL
NF-kB	NULL
through	NULL
the	NULL
CD14-dependent	NULL
pathway	NULL
utilized	NULL
by	NULL
LPS	NULL
.	NULL

The	NULL
present	NULL
studies	NULL
,	NULL
therefore	NULL
,	NULL
lend	NULL
additional	NULL
support	NULL
to	NULL
the	NULL
contention	NULL
that	NULL
spirochetal	NULL
lipoproteins	NULL
and	NULL
LPS	NULL
initiate	NULL
monocyte	NULL
activation	NULL
3846	NULL
NORGARD	NULL
ET	NULL
AL	NULL
.	NULL

via	NULL
different	NULL
cell	NULL
surface	NULL
events	NULL
but	NULL
that	NULL
these	NULL
signaling	NULL
pathways	NULL
ultimately	NULL
converge	NULL
to	NULL
produce	NULL
qualitatively	NULL
similar	NULL
cellular	NULL
responses	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Isolation	NULL
of	NULL
native	NULL
OspA	NULL
lipoprotein	NULL
from	NULL
B.	NULL
burgdorferi	NULL
.	NULL

B.	NULL
burgdorferi	NULL
TI-EV	NULL
,	NULL
generously	NULL
provided	NULL
by	NULL
Jorge	NULL
Benach	NULL
(	NULL
State	NULL
University	NULL
of	NULL
New	NULL
York	NULL
,	NULL
Stony	NULL
Brook	NULL
)	NULL
,	NULL
was	NULL
used	NULL
as	NULL
the	NULL
source	NULL
for	NULL
purification	NULL
of	NULL
native	NULL
OspA	NULL
;	NULL
this	NULL
strain	NULL
expresses	NULL
an	NULL
OspAB	NULL
chimera	NULL
which	NULL
includes	NULL
most	NULL
of	NULL
OspA	NULL
(	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
233	NULL
)	NULL
fused	NULL
via	NULL
an	NULL
aspartic	NULL
acid	NULL
residue	NULL
to	NULL
a	NULL
small	NULL
portion	NULL
of	NULL
the	NULL
C	NULL
terminus	NULL
of	NULL
OspB	NULL
(	NULL
amino	NULL
acids	NULL
257	NULL
to	NULL
296	NULL
)	NULL
.	NULL

B.	NULL
burgdorferi	NULL
was	NULL
cultivated	NULL
in	NULL
BSK	NULL
II	NULL
medium	NULL
at	NULL
34°C	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Care	NULL
was	NULL
exercised	NULL
to	NULL
minimize	NULL
contamination	NULL
by	NULL
environmental	NULL
LPS	NULL
during	NULL
the	NULL
purification	NULL
of	NULL
native	NULL
OspA	NULL
by	NULL
utilizing	NULL
baked	NULL
glassware	NULL
,	NULL
disposable	NULL
materials	NULL
,	NULL
and	NULL
endotoxin-free	NULL
water	NULL
to	NULL
prepare	NULL
all	NULL
buffers	NULL
and	NULL
reagents	NULL
.	NULL

OspA	NULL
was	NULL
purified	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Ma	NULL
and	NULL
Weis	NULL
(	NULL
37	NULL
)	NULL
as	NULL
modified	NULL
by	NULL
Jones	NULL
et	NULL
al	NULL
.	NULL

(	NULL
29	NULL
)	NULL
,	NULL
except	NULL
that	NULL
the	NULL
fractions	NULL
obtained	NULL
by	NULL
monoclonal	NULL
antibody	NULL
immuncaf-finity	NULL
chromatography	NULL
were	NULL
not	NULL
dialyzed	NULL
.	NULL

Fractions	NULL
were	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Protein	NULL
was	NULL
precipitated	NULL
by	NULL
addition	NULL
of	NULL
10	NULL
volumes	NULL
of	NULL
cold	NULL
acetone	NULL
(	NULL
and	NULL
incubation	NULL
overnight	NULL
at	NULL
-20°C	NULL
)	NULL
,	NULL
collected	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
air	NULL
dried	NULL
.	NULL

Protein	NULL
content	NULL
was	NULL
analyzed	NULL
by	NULL
the	NULL
bicinchoninic	NULL
acid	NULL
assay	NULL
method	NULL
(	NULL
Pierce	NULL
Chemical	NULL
Company	NULL
,	NULL
Rockford	NULL
,	NULL
IIL	NULL
)	NULL
and	NULL
by	NULL
comparison	NULL
with	NULL
known	NULL
quantities	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
stained	NULL
with	NULL
either	NULL
Coomassie	NULL
brilliant	NULL
blue	NULL
or	NULL
silver	NULL
following	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

The	NULL
yield	NULL
from	NULL
approximately	NULL
4	NULL
X	NULL
10	NULL
'	NULL
``	NULL
spirochetes	NULL
was	NULL
about	NULL
110	NULL
ug	NULL
of	NULL
protein	NULL
.	NULL

All	NULL
lipoprotein	NULL
samples	NULL
were	NULL
assayed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
contaminating	NULL
endotoxin	NULL
by	NULL
the	NULL
Limulus	NULL
amoebocyte	NULL
lysate	NULL
gelation	NULL
assay	NULL
(	NULL
E-Toxate	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

under	NULL
conditions	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
;	NULL
this	NULL
assay	NULL
routinely	NULL
detected	NULL
a	NULL
minimum	NULL
of	NULL
1.2	NULL
pg	NULL
of	NULL
endotoxin	NULL
.	NULL

Prior	NULL
to	NULL
addition	NULL
to	NULL
cell	NULL
cultures	NULL
,	NULL
OspA	NULL
was	NULL
suspended	NULL
by	NULL
vigorous	NULL
agitation	NULL
in	NULL
0.1	NULL
ml	NULL
of	NULL
prewarmed	NULL
(	NULL
37°C	NULL
)	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
(	NULL
final	NULL
endotoxin	NULL
contamination	NULL
due	NULL
to	NULL
FBS	NULL
was	NULL
less	NULL
than	NULL
0.2	NULL
pg/ml	NULL
)	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
nonlipidated	NULL
recombinant	NULL
OspA	NULL
from	NULL
E.	NULL
coli	NULL
.	NULL

A	NULL
nonacylated	NULL
recombinant	NULL
DNA-derived	NULL
fusion	NULL
protein	NULL
of	NULL
OspA	NULL
with	NULL
glutathione	NULL
S-transferase	NULL
was	NULL
constructed	NULL
in	NULL
£	NULL
.	NULL

coli	NULL
by	NULL
using	NULL
a	NULL
strategy	NULL
analogous	NULL
to	NULL
that	NULL
described	NULL
by	NULL
Radolf	NULL
et	NULL
al	NULL
.	NULL

(	NULL
48	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
PCR	NULL
amplification	NULL
of	NULL
B.	NULL
burgdorferi	NULL
TIL-EV	NULL
DNA	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
a	NULL
5	NULL
'	NULL
oligonucleotide	NULL
primer	NULL
for	NULL
the	NULL
ospA4	NULL
gene	NULL
(	NULL
5'-TTGGA	NULL
TCCTGTAAGCAAAATGTTAGCAGC-3	NULL
'	NULL
;	NULL
contains	NULL
a	NULL
5	NULL
'	NULL
BamHI	NULL
site	NULL
)	NULL
and	NULL
a	NULL
3	NULL
'	NULL
reverse	NULL
primer	NULL
(	NULL
5'-TTGAATTCCTAGCTGATGCCTTGTAGGG-3	NULL
'	NULL
;	NULL
has	NULL
no	NULL
BamHI	NULL
site	NULL
)	NULL
corresponding	NULL
to	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
ospB	NULL
gene	NULL
.	NULL

The	NULL
gel-purified	NULL
amplicon	NULL
was	NULL
digested	NULL
with	NULL
BemHI	NULL
and	NULL
then	NULL
ligated	NULL
into	NULL
the	NULL
BamHI	NULL
and	NULL
SmaI	NULL
sites	NULL
of	NULL
pGEX-2T	NULL
(	NULL
Pharmacia-LKB	NULL
Biotechnology	NULL
,	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
.	NULL

Following	NULL
transformation	NULL
in	NULL
£	NULL
.	NULL

coli	NULL
DHSa	NULL
,	NULL
one	NULL
clone	NULL
was	NULL
selected	NULL
(	NULL
designated	NULL
pDAA49.2	NULL
)	NULL
which	NULL
expressed	NULL
an	NULL
OspA-glutathione	NULL
S-transferase	NULL
fusion	NULL
protein	NULL
of	NULL
the	NULL
predicted	NULL
size	NULL
.	NULL

The	NULL
5°	NULL
and	NULL
3	NULL
'	NULL
junctions	NULL
of	NULL
the	NULL
construct	NULL
in	NULL
pGEX-2T	NULL
were	NULL
sequenced	NULL
(	NULL
300	NULL
bp	NULL
in	NULL
each	NULL
direction	NULL
)	NULL
to	NULL
verify	NULL
proper	NULL
genetic	NULL
construction	NULL
.	NULL

Expression	NULL
and	NULL
affinity	NULL
column	NULL
purification	NULL
of	NULL
the	NULL
glutathione	NULL
S-transferase	NULL
fusion	NULL
proteins	NULL
were	NULL
performed	NULL
by	NULL
standard	NULL
methods	NULL
(	NULL
60	NULL
)	NULL
.	NULL

The	NULL
nonacylated	NULL
spirochetal	NULL
proteins	NULL
were	NULL
cleaved	NULL
and	NULL
isolated	NULL
from	NULL
the	NULL
glutathione	NULL
S-transferase	NULL
moieties	NULL
by	NULL
thrombin	NULL
cleavage	NULL
of	NULL
the	NULL
immobilized	NULL
fusion	NULL
proteins	NULL
bound	NULL
to	NULL
glutathione	NULL
resin	NULL
(	NULL
70	NULL
)	NULL
.	NULL

To	NULL
remove	NULL
residual	NULL
£	NULL
.	NULL

colf	NULL
LPS	NULL
contaminants	NULL
from	NULL
the	NULL
nonacylated	NULL
recombinant	NULL
proteins	NULL
,	NULL
protein	NULL
solutions	NULL
were	NULL
subjected	NULL
to	NULL
Detoxi-Gel	NULL
Endotoxin	NULL
Removing	NULL
Gel	NULL
columns	NULL
(	NULL
Pierce	NULL
Chemical	NULL
Company	NULL
)	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Proteins	NULL
were	NULL
tested	NULL
by	NULL
the	NULL
Limulus	NULL
amoebocyte	NULL
lysate	NULL
gelation	NULL
assay	NULL
to	NULL
confirm	NULL
endotoxin	NULL
removal	NULL
.	NULL

Synthetic	NULL
peptides	NULL
and	NULL
lipopeptides	NULL
corresponding	NULL
to	NULL
the	NULL
N	NULL
termini	NULL
of	NULL
the	NULL
spirochetal	NULL
lipoproteins	NULL
.	NULL

Hexapeptides	NULL
corresponding	NULL
to	NULL
the	NULL
N	NULL
termini	NULL
of	NULL
the	NULL
47-kDa	NULL
(	NULL
Cys-Gly-Ser-Ser-His-His	NULL
)	NULL
(	NULL
70	NULL
)	NULL
and	NULL
17-kDa	NULL
(	NULL
Cys-Val-Ser-Cys-Thr-Thr	NULL
)	NULL
(	NULL
2	NULL
)	NULL
lipoproteins	NULL
of	NULL
7.	NULL
pellidum	NULL
subsp	NULL
.	NULL

pallidum	NULL
(	NULL
designated	NULL
Tpp47	NULL
and	NULL
Tpp17	NULL
,	NULL
respectively	NULL
)	NULL
and	NULL
the	NULL
OspA	NULL
(	NULL
Cys-Lys-GIn-Asn-Val-Ser	NULL
)	NULL
and	NULL
OspB	NULL
(	NULL
Cys-Ala-Gin-Lys-Gly-Ala	NULL
)	NULL
lipoproteins	NULL
of	NULL
B.	NULL
burgdorferi	NULL
(	NULL
8	NULL
)	NULL
were	NULL
synthesized	NULL
on	NULL
an	NULL
Applied	NULL
Biosystems	NULL
(	NULL
Foster	NULL
City	NULL
,	NULL
Calif.	NULL
)	NULL
430A	NULL
peptide	NULL
synthesizer	NULL
using	NULL
standard	NULL
9-flu-orenylmethoxycarbonyl	NULL
chemistry	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

For	NULL
use	NULL
in	NULL
cell	NULL
stimulation	NULL
assays	NULL
,	NULL
quantities	NULL
of	NULL
dry	NULL
hexapeptides	NULL
were	NULL
solubilized	NULL
by	NULL
vortexing	NULL
in	NULL
sterile	NULL
,	NULL
endotoxin-free	NULL
water	NULL
.	NULL

Inasmuch	NULL
as	NULL
palmitate	NULL
is	NULL
the	NULL
principal	NULL
long-chain	NULL
fatty	NULL
acid	NULL
of	NULL
the	NULL
native	NULL
spirochetal	NULL
lipoproteins	NULL
(	NULL
7	NULL
)	NULL
,	NULL
lipohexapeptide	NULL
analogs	NULL
corresponding	NULL
to	NULL
the	NULL
acylated	NULL
N	NULL
termini	NULL
of	NULL
the	NULL
lipoproteins	NULL
were	NULL
synthesized	NULL
as	NULL
tripalmitoy	NULL
]	NULL
derivatives	NULL
by	NULL
using	NULL
a	NULL
solid-phase	NULL
synthesis	NULL
procedure	NULL
(	NULL
14	NULL
)	NULL
.	NULL

All	NULL
synthetic	NULL
peptides	NULL
and	NULL
lipopeptides	NULL
were	NULL
assayed	NULL
for	NULL
contaminating	NULL
LPS	NULL
by	NULL
the	NULL
Limulus	NULL
amoebocyte	NULL
lysate	NULL
gelation	NULL
assay	NULL
after	NULL
being	NULL
dissolved	NULL
or	NULL
suspended	NULL
in	NULL
sterile	NULL
,	NULL
endotoxin-free	NULL
water	NULL
.	NULL

As	NULL
were	NULL
the	NULL
native	NULL
lipoproteins	NULL
,	NULL
synthetic	NULL
lipopeptides	NULL
were	NULL
dissolved	NULL
in	NULL
prewarmed	NULL
FBS	NULL
prior	NULL
to	NULL
addition	NULL
to	NULL
cell	NULL
cultures	NULL
.	NULL

Cell	NULL
culture	NULL
.	NULL

The	NULL
THP-1	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
(	NULL
66	NULL
)	NULL
,	NULL
obtained	NULL
from	NULL
Robert	NULL
S.	NULL
Munford	NULL
and	NULL
Richard	NULL
Kitchens	NULL
(	NULL
University	NULL
of	NULL
Texas	NULL
Southwestern	NULL
Medical	NULL
Center	NULL
,	NULL
Dallas	NULL
)	NULL
,	NULL
was	NULL
maintained	NULL
and	NULL
cultured	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Some	NULL
experiments	NULL
were	NULL
conducted	NULL
with	NULL
THP-1	NULL
cells	NULL
to	NULL
evaluate	NULL
the	NULL
influence	NULL
of	NULL
vitamin	NULL
D	NULL
;	NULL
treatment	NULL
(	NULL
0.1	NULL
M	NULL
for	NULL
72	NULL
h	NULL
,	NULL
followed	NULL
by	NULL
retreatment	NULL
for	NULL
an	NULL
additional	NULL
24	NULL
h	NULL
)	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
prior	NULL
to	NULL
stimulation	NULL
of	NULL
adherent	NULL
cells	NULL
for	NULL
4	NULL
h	NULL
by	NULL
LPS	NULL
,	NULL
peptides	NULL
,	NULL
lipoproteins	NULL
,	NULL
or	NULL
lipopeptides	NULL
.	NULL

Rough	NULL
bacterial	NULL
LPS	NULL
(	NULL
from	NULL
Salmonella	NULL
minnesota	NULL
R5	NULL
[	NULL
Re	NULL
mutant	NULL
]	NULL
;	NULL
molecular	NULL
weight	NULL
,	NULL
ca	NULL
.	NULL

4,000	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
catalog	NULL
no	NULL
.	NULL

InFECT	NULL
.	NULL

ImnmUN	NULL
.	NULL

L-8893	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
in	NULL
all	NULL
cell	NULL
stimulation	NULL
assays	NULL
.	NULL

Preincubation	NULL
(	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
)	NULL
of	NULL
proteins	NULL
,	NULL
lipoproteins	NULL
,	NULL
peptides	NULL
,	NULL
lipopeptides	NULL
,	NULL
and	NULL
LPS	NULL
with	NULL
polymyxin	NULL
B	NULL
(	NULL
PB	NULL
;	NULL
10	NULL
pg/ml	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
was	NULL
used	NULL
to	NULL
abrogate	NULL
the	NULL
effect	NULL
of	NULL
LPS	NULL
or	NULL
LPS	NULL
contaminants	NULL
.	NULL

Murine	NULL
lymphoma	NULL
70Z/3	NULL
pre-B	NULL
cells	NULL
(	NULL
45	NULL
)	NULL
transfected	NULL
with	NULL
either	NULL
the	NULL
human	NULL
CD14	NULL
gene	NULL
(	NULL
hCD14	NULL
)	NULL
or	NULL
the	NULL
pRe/RSV	NULL
expression	NULL
vector	NULL
alone	NULL
(	NULL
33	NULL
)	NULL
were	NULL
generously	NULL
provided	NULL
by	NULL
Richard	NULL
Ulevitch	NULL
(	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

70Z/3-derived	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
30	NULL
,	NULL
45	NULL
)	NULL
.	NULL

U1	NULL
cells	NULL
,	NULL
a	NULL
subclone	NULL
of	NULL
the	NULL
promonocytic	NULL
cell	NULL
line	NULL
U937	NULL
latently	NULL
infected	NULL
with	NULL
HIV	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
(	NULL
17	NULL
)	NULL
,	NULL
were	NULL
used	NULL
to	NULL
assess	NULL
induction	NULL
of	NULL
HIV-1	NULL
by	NULL
7.	NULL
pallidum	NULL
lipopeptides	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
1	NULL
%	NULL
glutamine	NULL
,	NULL
and	NULL
a	NULL
1	NULL
%	NULL
penicillin-streptomycin	NULL
solution	NULL
.	NULL

All	NULL
reagents	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
free	NULL
of	NULL
endotoxin	NULL
.	NULL

Detection	NULL
of	NULL
interleukin-1B	NULL
(	NULL
IL-1B	NULL
)	NULL
transcripts	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
stimulated	NULL
cells	NULL
by	NULL
using	NULL
the	NULL
Ultraspec	NULL
RNA	NULL
isolation	NULL
system	NULL
(	NULL
Biotecx	NULL
Laboratories	NULL
,	NULL
Inc.	NULL
,	NULL
Houston	NULL
,	NULL
Tex	NULL
.	NULL
)	NULL

as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

RNA	NULL
was	NULL
dissolved	NULL
in	NULL
sterile	NULL
,	NULL
deionized	NULL
water	NULL
(	NULL
treated	NULL
with	NULL
0.1	NULL
%	NULL
diethylpyrocarbon-ate	NULL
)	NULL
and	NULL
quantitated	NULL
spectrophotometrically	NULL
(	NULL
55	NULL
)	NULL
.	NULL

To	NULL
20	NULL
ug	NULL
of	NULL
RNA	NULL
in	NULL
11	NULL
al	NULL
of	NULL
water	NULL
were	NULL
added	NULL
5	NULL
pl	NULL
of	NULL
10x	NULL
MOPS	NULL
buffer	NULL
[	NULL
0.4	NULL
M	NULL
3-	NULL
(	NULL
N-morpholino	NULL
)	NULL
propane-sulfonic	NULL
acid	NULL
,	NULL
0.1	NULL
M	NULL
sodium	NULL
acetate	NULL
,	NULL
0.01	NULL
M	NULL
EDTA	NULL
]	NULL
,	NULL
9	NULL
pl	NULL
of	NULL
12.3	NULL
M	NULL
formalde-hyde	NULL
,	NULL
and	NULL
25	NULL
pil	NULL
of	NULL
deionized	NULL
formamide	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
65°C	NULL
and	NULL
chilled	NULL
on	NULL
ice	NULL
,	NULL
and	NULL
then	NULL
10	NULL
pl	NULL
of	NULL
formaldehyde	NULL
loading	NULL
buffer	NULL
(	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.25	NULL
%	NULL
[	NULL
wt/vol	NULL
]	NULL
bromophenol	NULL
blue	NULL
,	NULL
50	NULL
%	NULL
glycerol	NULL
)	NULL
was	NULL
added	NULL
.	NULL

RNA	NULL
in	NULL
this	NULL
mixture	NULL
was	NULL
resolved	NULL
by	NULL
using	NULL
standard	NULL
formaldehyde	NULL
buffer	NULL
(	NULL
1X	NULL
MOPS	NULL
buffer	NULL
,	NULL
0.666	NULL
%	NULL
[	NULL
vol/vol	NULL
]	NULL
formaldehyde	NULL
)	NULL
and	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
conditions	NULL
(	NULL
55	NULL
)	NULL
.	NULL

A	NULL
lane	NULL
containing	NULL
RNA	NULL
ladder	NULL
molecular	NULL
size	NULL
markers	NULL
(	NULL
0.24	NULL
to	NULL
9.5	NULL
kb	NULL
)	NULL
(	NULL
Gibco-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

was	NULL
trimmed	NULL
away	NULL
from	NULL
the	NULL
gel	NULL
,	NULL
stained	NULL
with	NULL
ethidium	NULL
bromide	NULL
,	NULL
and	NULL
photographed	NULL
for	NULL
estimation	NULL
of	NULL
molecular	NULL
sizes	NULL
of	NULL
hybridizing	NULL
RNA	NULL
transcripts	NULL
.	NULL

RNA	NULL
was	NULL
transferred	NULL
to	NULL
a	NULL
Hybond-N	NULL
*	NULL
charged	NULL
nylon	NULL
membrane	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IIL	NULL
)	NULL
in	NULL
20	NULL
%	NULL
SSC	NULL
(	NULL
1	NULL
%	NULL
SSC	NULL
is	NULL
0.15	NULL
M	NULL
NaCl	NULL
plus	NULL
0.015	NULL
M	NULL
sodium	NULL
citrate	NULL
)	NULL
buffer	NULL
via	NULL
the	NULL
capillary	NULL
method	NULL
and	NULL
UV	NULL
cross-linked	NULL
to	NULL
the	NULL
membrane	NULL
.	NULL

Hybridization	NULL
and	NULL
washing	NULL
of	NULL
the	NULL
membranes	NULL
were	NULL
carried	NULL
out	NULL
essentially	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
hybridization	NULL
was	NULL
performed	NULL
at	NULL
42°C	NULL
overnight	NULL
in	NULL
5	NULL
%	NULL
SSC	NULL
buffer-5	NULL
%	NULL
Denhardt	NULL
's	NULL
solution-1	NULL
%	NULL
SDS-50	NULL
%	NULL
formamide-1	NULL
mg	NULL
of	NULL
salmon	NULL
sperm	NULL
DNA	NULL
per	NULL
ml	NULL
.	NULL

Probes	NULL
for	NULL
IL-1B	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
catalog	NULL
no	NULL
.	NULL

67024	NULL
)	NULL
(	NULL
5	NULL
)	NULL
and	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
catalog	NULL
no	NULL
.	NULL

57090	NULL
)	NULL
(	NULL
72	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
relevant	NULL
plasmid	NULL
DNAs	NULL
;	NULL
they	NULL
were	NULL
radiolabeled	NULL
with	NULL
[	NULL
«	NULL
-	NULL
``	NULL
P	NULL
]	NULL
JdCTP	NULL
by	NULL
using	NULL
the	NULL
Boehringer	NULL
Mannheim	NULL
(	NULL
Indianapolis	NULL
,	NULL
Ind	NULL
.	NULL
)	NULL

random	NULL
DNA	NULL
primer	NULL
labeling	NULL
kit	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Washing	NULL
of	NULL
filters	NULL
was	NULL
performed	NULL
at	NULL
room	NULL
temperature	NULL
by	NULL
two	NULL
serial	NULL
washes	NULL
with	NULL
2	NULL
%	NULL
SSC	NULL
buffer-0.1	NULL
%	NULL
SDS	NULL
followed	NULL
by	NULL
one	NULL
wash	NULL
at	NULL
42°C	NULL
with	NULL
0.2	NULL
%	NULL
SSC-0.1	NULL
%	NULL
SDS	NULL
.	NULL

Membranes	NULL
were	NULL
then	NULL
dried	NULL
and	NULL
subjected	NULL
to	NULL
autoradiography	NULL
at	NULL
-70°C	NULL
for	NULL
various	NULL
times	NULL
.	NULL

NF-xB	NULL
assays	NULL
.	NULL

The	NULL
active	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
translocated	NULL
into	NULL
the	NULL
nuclei	NULL
of	NULL
stimulated	NULL
cells	NULL
,	NULL
was	NULL
detected	NULL
by	NULL
incubating	NULL
nuclear	NULL
extracts	NULL
from	NULL
stimulated	NULL
cells	NULL
with	NULL
a	NULL
radiolabeled	NULL
target	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
followed	NULL
by	NULL
a	NULL
gel	NULL
retardation	NULL
assay	NULL
;	NULL
cell	NULL
stimulations	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
cell	NULL
lysates	NULL
,	NULL
and	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
31	NULL
)	NULL
.	NULL

THP-1	NULL
cells	NULL
typically	NULL
were	NULL
stimulated	NULL
for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
70Z/3	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Surface	NULL
immunoglobulin	NULL
M	NULL
(	NULL
IgM	NULL
)	NULL
expression	NULL
by	NULL
activated	NULL
70Z/3	NULL
cells	NULL
.	NULL

Surface	NULL
IgM	NULL
expression	NULL
by	NULL
stimulated	NULL
702Z/3	NULL
cells	NULL
was	NULL
assessed	NULL
by	NULL
fluorescent	NULL
cell	NULL
staining	NULL
and	NULL
flow	NULL
cytometry	NULL
essentially	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
59	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
702	NULL
,	NULL
/3	NULL
cells	NULL
were	NULL
plated	NULL
at	NULL
a	NULL
final	NULL
density	NULL
of	NULL
2	NULL
X	NULL
10°	NULL
per	NULL
well	NULL
in	NULL
24-well	NULL
plates	NULL
.	NULL

After	NULL
stimulation	NULL
for	NULL
24	NULL
h	NULL
with	NULL
various	NULL
agents	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
by	NULL
centrifugation	NULL
,	NULL
suspended	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
-1	NULL
%	NULL
FBS	NULL
,	NULL
and	NULL
enumerated	NULL
,	NULL
and	NULL
10°	NULL
cells	NULL
were	NULL
distributed	NULL
into	NULL
sterile	NULL
polystyrene	NULL
tubes	NULL
.	NULL

After	NULL
being	NULL
washed	NULL
twice	NULL
by	NULL
centrifugation	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
PBS-1	NULL
%	NULL
FBS	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stained	NULL
for	NULL
30	NULL
min	NULL
(	NULL
4°C	NULL
)	NULL
by	NULL
addition	NULL
of	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
goat	NULL
anti-mouse	NULL
IgM	NULL
,	NULL
washed	NULL
thrice	NULL
by	NULL
centrifugation	NULL
in	NULL
cold	NULL
PBS-1	NULL
%	NULL
FBS	NULL
,	NULL
and	NULL
resus-pended	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
cold	NULL
PBS-1	NULL
%	NULL
FBS	NULL
.	NULL

They	NULL
then	NULL
were	NULL
transferred	NULL
to	NULL
fresh	NULL
polystyrene	NULL
tubes	NULL
(	NULL
kept	NULL
on	NULL
ice	NULL
and	NULL
protected	NULL
from	NULL
light	NULL
)	NULL
and	NULL
analyzed	NULL
with	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
Immunocytometry	NULL
Systems	NULL
,	NULL
Mans-field	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

.	NULL

Assay	NULL
for	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
.	NULL

To	NULL
assay	NULL
for	NULL
HIV-1	NULL
induction	NULL
in	NULL
U1	NULL
cells	NULL
,	NULL
triplicate	NULL
cultures	NULL
containing	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
were	NULL
grown	NULL
in	NULL
complete	NULL
culture	NULL
medium	NULL
or	NULL
the	NULL
same	NULL
medium	NULL
supplemented	NULL
with	NULL
either	NULL
LPS	NULL
(	NULL
200	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
spirochetal	NULL
peptides	NULL
or	NULL
lipopeptides	NULL
(	NULL
30	NULL
M	NULL
)	NULL
.	NULL

Cell-free	NULL
culture	NULL
supernatants	NULL
were	NULL
collected	NULL
48	NULL
h	NULL
poststimulation	NULL
and	NULL
assayed	NULL
for	NULL
the	NULL
HIV-1	NULL
p24	NULL
antigen	NULL
with	NULL
the	NULL
Alliance	NULL
HIV-p24	NULL
ELISA	NULL
Kit	NULL
(	NULL
Du	NULL
Pont	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

.	NULL

Statistical	NULL
analysis	NULL
of	NULL
the	NULL
assay	NULL
results	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
Fisher	NULL
's	NULL
least	NULL
significant	NULL
difference	NULL
.	NULL

RESULTS	NULL
For	NULL
our	NULL
comparative	NULL
studies	NULL
of	NULL
cell	NULL
activation	NULL
by	NULL
LPS	NULL
and	NULL
spirochetal	NULL
lipoproteins	NULL
and	NULL
lipopeptides	NULL
,	NULL
it	NULL
was	NULL
considered	NULL
advantageous	NULL
to	NULL
employ	NULL
the	NULL
well-characterized	NULL
THP-1	NULL
human	NULL
monocytoid	NULL
cell	NULL
line	NULL
(	NULL
3	NULL
,	NULL
66	NULL
)	NULL
.	NULL

At	NULL
the	NULL
outset	NULL
,	NULL
it	NULL
was	NULL
necessary	NULL
to	NULL
determine	NULL
whether	NULL
this	NULL
cell	NULL
line	NULL
was	NULL
responsive	NULL
to	NULL
spirochetal	NULL
lipopeptides	NULL
and	NULL
lipoproteins	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lipopeptides	NULL
VoL	NULL
.	NULL

64	NULL
,	NULL
1996	NULL
ss	NULL
ag	NULL
5	NULL
54	NULL
17L	NULL
1	NULL
G	NULL
OspA-L	NULL
a	NULL
a	NULL
'	NULL
1	NULL
o	NULL
o	NULL
1	NULL
u	NULL
o	NULL
a	NULL
o	NULL
a	NULL
o	NULL
choo	NULL
p	NULL
9	NULL
9	NULL
cao	NULL
9	NULL
Q9	NULL
9	NULL
9	NULL
-	NULL
m	NULL
2	NULL
-in	NULL
~	NULL
06	NULL
8	NULL
-	NULL
-n	NULL
-	NULL
6	NULL
8	NULL
ILt-B	NULL
®	NULL
'	NULL
©	NULL
=	NULL
+	NULL
Vit	NULL
.	NULL

D3	NULL
sar	NULL
:	NULL
W	NULL
IL1-B	NULL
-	NULL
Vit	NULL
.	NULL

D3	NULL
car	NULL
:	NULL
#	NULL
00000	NULL
#	NULL
00000	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Responsiveness	NULL
of	NULL
THP-1	NULL
cells	NULL
to	NULL
graded	NULL
doses	NULL
of	NULL
spirochetal	NULL
lipopeptides	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
either	NULL
treated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
treated	NULL
(	NULL
-	NULL
)	NULL
with	NULL
vitamin	NULL
(	NULL
Vit	NULL
)	NULL
D	NULL
;	NULL
;	NULL
1-ml	NULL
subcultures	NULL
were	NULL
then	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
various	NULL
doses	NULL
(	NULL
shown	NULL
in	NULL
micrograms	NULL
per	NULL
milliliter	NULL
at	NULL
the	NULL
top	NULL
)	NULL
of	NULL
LPS	NULL
(	NULL
positive	NULL
control	NULL
)	NULL
or	NULL
lipopeptides	NULL
corresponding	NULL
to	NULL
Tpp17	NULL
(	NULL
171	NULL
)	NULL
and	NULL
OspA	NULL
(	NULL
OspA-L	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
isolated	NULL
and	NULL
hybridized	NULL
in	NULL
Northern	NULL
(	NULL
RNA	NULL
)	NULL
blots	NULL
with	NULL
a	NULL
radiolabeled	NULL
probe	NULL
for	NULL
either	NULL
IL-1	NULL
or	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
,	NULL
the	NULL
gene	NULL
for	NULL
which	NULL
is	NULL
constitutively	NULL
expressed	NULL
.	NULL

For	NULL
lipopeptides	NULL
,	NULL
1.0	NULL
g/ml	NULL
corresponds	NULL
to	NULL
ca	NULL
.	NULL

0.71	NULL
M.	NULL
based	NULL
upon	NULL
the	NULL
N	NULL
termini	NULL
of	NULL
OspA	NULL
and	NULL
Tpp17	NULL
induced	NULL
IL-18B	NULL
mRNA	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
.	NULL

Vitamin	NULL
D	NULL
,	NULL
maturation	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
enhance	NULL
the	NULL
LPS	NULL
responsiveness	NULL
of	NULL
THP-1	NULL
cells	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
,	NULL
also	NULL
enhanced	NULL
the	NULL
sensitivity	NULL
of	NULL
the	NULL
cells	NULL
to	NULL
lipopeptides	NULL
.	NULL

Consistent	NULL
with	NULL
earlier	NULL
findings	NULL
(	NULL
14	NULL
,	NULL
51	NULL
)	NULL
,	NULL
the	NULL
corresponding	NULL
nonlipidated	NULL
peptides	NULL
were	NULL
without	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Essentially	NULL
identical	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
lipopeptides	NULL
based	NULL
upon	NULL
OspB	NULL
and	NULL
Tpp47	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
with	NULL
purified	NULL
OspA	NULL
(	NULL
32	NULL
nM	NULL
;	NULL
ca	NULL
.	NULL

1	NULL
pg/ml	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
which	NULL
,	NULL
by	NULL
the	NULL
Limulus	NULL
amoebocyte	NULL
lysate	NULL
gelation	NULL
as-say	NULL
,	NULL
contained	NULL
a	NULL
level	NULL
of	NULL
endotoxin	NULL
contamination	NULL
(	NULL
<	NULL
12	NULL
pg/ug	NULL
of	NULL
protein	NULL
)	NULL
well	NULL
below	NULL
that	NULL
capable	NULL
of	NULL
activating	NULL
THP-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

(	NULL
OspA	NULL
was	NULL
selected	NULL
as	NULL
a	NULL
representative	NULL
spirochetal	NULL
lipoprotein	NULL
because	NULL
of	NULL
the	NULL
relative	NULL
ease	NULL
with	NULL
which	NULL
it	NULL
can	NULL
be	NULL
purified	NULL
without	NULL
endotoxin	NULL
contamination	NULL
.	NULL
)	NULL

Upon	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
above-described	NULL
findings	NULL
,	NULL
subsequent	NULL
experiments	NULL
utilized	NULL
only	NULL
vitamin	NULL
D	NULL
,	NULL
-treated	NULL
cells	NULL
.	NULL

We	NULL
next	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
signaling	NULL
events	NULL
associated	NULL
with	NULL
LPS-mediated	NULL
cell	NULL
activation	NULL
also	NULL
occur	NULL
during	NULL
cell	NULL
activation	NULL
by	NULL
spirochetal	NULL
lipoproteins-lipopeptides	NULL
.	NULL

We	NULL
chose	NULL
to	NULL
study	NULL
the	NULL
activation	NULL
and	NULL
translocation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
,	NULL
a	NULL
sentinel	NULL
event	NULL
in	NULL
LPS-mediated	NULL
signaling	NULL
(	NULL
34	NULL
,	NULL
41	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
examined	NULL
extensively	NULL
in	NULL
THP-1	NULL
cells	NULL
(	NULL
31	NULL
)	NULL
.	NULL

In	NULL
our	NULL
earlier	NULL
studies	NULL
,	NULL
it	NULL
was	NULL
established	NULL
that	NULL
lipopeptides	NULL
at	NULL
10	NULL
wM	NULL
and	NULL
LPS	NULL
at	NULL
10	NULL
nM	NULL
were	NULL
approximately	NULL
equivalent	NULL
with	NULL
respect	NULL
to	NULL
induction	NULL
of	NULL
cytokine	NULL
production	NULL
by	NULL
murine	NULL
and	NULL
human	NULL
macrophages	NULL
(	NULL
51	NULL
)	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
either	NULL
LPS	NULL
or	NULL
four	NULL
representative	NULL
spirochetal	NULL
lipopeptides	NULL
(	NULL
as	NULL
well	NULL
as	NULL
nonlipidated	NULL
peptide	NULL
controls	NULL
)	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
for	NULL
gel	NULL
retardation	NULL
assays	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
LPS	NULL
and	NULL
all	NULL
four	NULL
acylated	NULL
peptides	NULL
promoted	NULL
NF-kB	NULL
translo-	NULL
MONOCYTE	NULL
ACTIVATION	NULL
BY	NULL
LIPOPROTEINS	NULL
AND	NULL
LIPOPEPTIDES	NULL
3847	NULL
A	NULL
Polymyxin	NULL
B	NULL
_-	NULL
J	NULL
_	NULL
-	NULL
O4	NULL
-	NULL
_-	NULL
<	NULL
0	NULL
0	NULL
fo-LPS	NULL
LPS	NULL
47L	NULL
47L	NULL
47	NULL
Neg	NULL
.	NULL

17L	NULL
17L	NULL
17	NULL
-	NULL
WW	NULL
-	NULL
WW	NULL
ludt	NULL
``	NULL
N~..	NULL
B	NULL
Polymyxin	NULL
B	NULL
=o	NULL
oe	NULL
4p	NULL
oe	NULL
4	NULL
c=	NULL
<	NULL
0	NULL
4p	NULL
o-407	NULL
40	NULL
4	NULL
4	NULL
<	NULL
4	NULL
m	NULL
m	NULL
a	NULL
m	NULL
®	NULL
®	NULL
a	NULL
&	NULL
A	NULL
a	NULL
aA	NULL
2A	NULL
a	NULL
0	NULL
a	NULL
-	NULL
9	NULL
a	NULL
9	NULL
J	NULL
a	NULL
a	NULL
5	NULL
5	NULL
0	NULL
Oo	NULL
0	NULL
o	NULL
O	NULL
o	NULL
b	NULL
bat	NULL
you	NULL
bud	NULL
bud	NULL
as	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Synthetic	NULL
lipopeptides	NULL
corresponding	NULL
to	NULL
7.	NULL
pallidum	NULL
(	NULL
A	NULL
)	NULL
and	NULL
B.	NULL
burgdorferi	NULL
(	NULL
B	NULL
)	NULL
lipoproteins	NULL
induce	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

THP-1	NULL
monocytoid	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
10	NULL
uM	NULL
(	NULL
ca	NULL
.	NULL

14	NULL
pg/ml	NULL
)	NULL
of	NULL
lipopeptides	NULL
corresponding	NULL
to	NULL
Tpp47	NULL
(	NULL
471	NULL
)	NULL
,	NULL
Tpp17	NULL
(	NULL
171	NULL
)	NULL
,	NULL
OspA	NULL
(	NULL
OspA-L	NULL
)	NULL
,	NULL
and	NULL
OspB	NULL
(	NULL
OspB-L	NULL
)	NULL
or	NULL
10	NULL
wM	NULL
(	NULL
ca	NULL
.	NULL

6	NULL
ug/ml	NULL
!	NULL
)	NULL

nonacylated	NULL
control	NULL
hexapeptides	NULL
(	NULL
lanes	NULL
47	NULL
,	NULL
17	NULL
,	NULL
OspA	NULL
,	NULL
and	NULL
OspB	NULL
)	NULL
in	NULL
either	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
PB	NULL
.	NULL

LPS	NULL
(	NULL
10	NULL
nM	NULL
;	NULL
40	NULL
ng/m	NULL
!	NULL
)	NULL

was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

Activated	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
nuclear	NULL
extracts	NULL
was	NULL
assessed	NULL
by	NULL
gel	NULL
retardation	NULL
assay	NULL
;	NULL
the	NULL
arrow	NULL
indicates	NULL
the	NULL
retarded	NULL
radiolabeled	NULL
target	NULL
oligonucleo-tide	NULL
.	NULL

Neg	NULL
.	NULL

,	NULL
unstimulated	NULL
control	NULL
culture	NULL
.	NULL

cation	NULL
,	NULL
whereas	NULL
the	NULL
nonlipidated	NULL
peptides	NULL
did	NULL
not	NULL
.	NULL

Consistent	NULL
with	NULL
prior	NULL
findings	NULL
(	NULL
50	NULL
,	NULL
51	NULL
)	NULL
,	NULL
PB	NULL
abrogated	NULL
only	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
LPS	NULL
.	NULL

Additional	NULL
kinetic	NULL
studies	NULL
revealed	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
in	NULL
response	NULL
to	NULL
both	NULL
LPS	NULL
and	NULL
lipopeptides	NULL
was	NULL
detectable	NULL
within	NULL
15	NULL
min	NULL
poststimulation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
obtain	NULL
further	NULL
evidence	NULL
supporting	NULL
the	NULL
use	NULL
of	NULL
lipopeptides	NULL
as	NULL
surrogates	NULL
for	NULL
lipoproteins	NULL
in	NULL
studies	NULL
of	NULL
immune	NULL
cell	NULL
activation	NULL
(	NULL
14	NULL
,	NULL
51	NULL
)	NULL
,	NULL
we	NULL
also	NULL
examined	NULL
the	NULL
translocation	NULL
of	NULL
NF-KB	NULL
in	NULL
response	NULL
to	NULL
OspA	NULL
purified	NULL
from	NULL
B.	NULL
burgdorferi	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
OspA	NULL
lipopeptide	NULL
,	NULL
translocation	NULL
of	NULL
NF-kB	NULL
after	NULL
incubation	NULL
with	NULL
OspA	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
PB	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

It	NULL
is	NULL
of	NULL
particular	NULL
importance	NULL
that	NULL
,	NULL
as	NULL
with	NULL
the	NULL
synthetic	NULL
analogs	NULL
,	NULL
OspA-mediated	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
was	NULL
observed	NULL
only	NULL
with	NULL
the	NULL
lipid-modified	NULL
polypeptide	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Previous	NULL
evidence	NULL
suggested	NULL
that	NULL
LPS	NULL
and	NULL
spirochetal	NULL
lipoproteins-lipopeptides	NULL
stimulate	NULL
cytokine	NULL
production	NULL
via	NULL
dif-	NULL
3848	NULL
NORGARD	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
nOspA	NULL
rOspA	NULL
92.5	NULL
69	NULL
46	NULL
30	NULL
.-	NULL
-mm	NULL
»	NULL
.me	NULL
.	NULL

21.5	NULL
14.3	NULL
B	NULL
Polymyxin	NULL
B	NULL
_-	NULL
__+	NULL
_-	NULL
as	NULL
T4	NULL
4	NULL
4G	NULL
TI	NULL
&	NULL
_	NULL
&	NULL
A	NULL
a	NULL
ao	NULL
a	NULL
2	NULL
g	NULL
5	NULL
8	NULL
$	NULL
$	NULL
4299	NULL
g	NULL
-	NULL
C	NULL
w	NULL
o	NULL
.	NULL

-	NULL
]	NULL
-	NULL
®	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Native	NULL
OspA	NULL
from	NULL
B.	NULL
burgdorferi	NULL
induces	NULL
NF-kB	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Samples	NULL
(	NULL
0.75	NULL
ug	NULL
)	NULL
of	NULL
either	NULL
native	NULL
OspA	NULL
purified	NULL
from	NULL
B.	NULL
burgdorferi	NULL
or	NULL
nonacylated	NULL
,	NULL
recombinant	NULL
OspA	NULL
isolated	NULL
from	NULL
£	NULL
.	NULL

coli	NULL
were	NULL
resolved	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
stained	NULL
with	NULL
silver	NULL
.	NULL

Molecular	NULL
masses	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
in	NULL
kilodaltons	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
THP-1	NULL
cells	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
32	NULL
nM	NULL
(	NULL
ca	NULL
.	NULL

1	NULL
g/m	NULL
!	NULL
)	NULL

native	NULL
or	NULL
nonacylated	NULL
recombinant	NULL
OspA	NULL
(	NULL
nOspA	NULL
and	NULL
rOspA	NULL
,	NULL
respectively	NULL
)	NULL
or	NULL
LPS	NULL
(	NULL
10	NULL
nM	NULL
;	NULL
40	NULL
ng/m	NULL
!	NULL
)	NULL

in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
PB	NULL
.	NULL

Neg	NULL
.	NULL

,	NULL
unstimulated	NULL
control	NULL
culture	NULL
.	NULL

ferent	NULL
cell	NULL
surface	NULL
events	NULL
(	NULL
51	NULL
)	NULL
.	NULL

To	NULL
garner	NULL
additional	NULL
support	NULL
for	NULL
this	NULL
notion	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
the	NULL
CD14-dependent	NULL
pathway	NULL
utilized	NULL
by	NULL
LPS	NULL
in	NULL
cell	NULL
activation	NULL
by	NULL
spirochetal	NULL
lipoproteins-lipopeptides	NULL
.	NULL

Binding	NULL
of	NULL
LPS	NULL
(	NULL
complexed	NULL
to	NULL
LPS-binding	NULL
protein	NULL
)	NULL
to	NULL
the	NULL
CD14	NULL
receptor	NULL
is	NULL
the	NULL
initial	NULL
event	NULL
in	NULL
macrophage	NULL
activation	NULL
(	NULL
67	NULL
)	NULL
;	NULL
CD14	NULL
also	NULL
has	NULL
been	NULL
implicated	NULL
as	NULL
a	NULL
pattern	NULL
recognition	NULL
receptor	NULL
for	NULL
other	NULL
bacterial	NULL
cell	NULL
wall	NULL
constituents	NULL
with	NULL
immunostimulatory	NULL
activities	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
CD14-negative	NULL
murine	NULL
pre-B-cell	NULL
line	NULL
70Z/3	NULL
and	NULL
the	NULL
same	NULL
cells	NULL
transfected	NULL
with	NULL
hCD14	NULL
(	NULL
33	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
described	NULL
(	NULL
33	NULL
)	NULL
,	NULL
LPS	NULL
at	NULL
40	NULL
ng/ml	NULL
failed	NULL
to	NULL
induce	NULL
NF-kB	NULL
translocation	NULL
during	NULL
a	NULL
30-min	NULL
incubation	NULL
with	NULL
CD14-negative	NULL
70Z/3	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Lipopeptides	NULL
corresponding	NULL
to	NULL
OspA	NULL
and	NULL
Tpp17	NULL
also	NULL
were	NULL
without	NULL
effect	NULL
at	NULL
concentrations	NULL
of	NULL
up	NULL
to	NULL
100	NULL
wM	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
transfection	NULL
of	NULL
70Z/3	NULL
cells	NULL
with	NULL
hCD14	NULL
imparted	NULL
responsiveness	NULL
to	NULL
the	NULL
same	NULL
low	NULL
dose	NULL
of	NULL
LPS	NULL
but	NULL
not	NULL
to	NULL
the	NULL
two	NULL
spirochetal	NULL
lipopeptides	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
InFECT	NULL
.	NULL

ImnmUN	NULL
.	NULL

using	NULL
cells	NULL
incubated	NULL
with	NULL
LPS	NULL
and	NULL
lipopeptides	NULL
for	NULL
1	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
CD14	NULL
transfection	NULL
imparted	NULL
responsiveness	NULL
to	NULL
LPS	NULL
but	NULL
not	NULL
to	NULL
lipopeptides	NULL
was	NULL
supported	NULL
by	NULL
examining	NULL
the	NULL
induction	NULL
of	NULL
surface	NULL
IgM	NULL
expression	NULL
as	NULL
an	NULL
alternative	NULL
activation	NULL
marker	NULL
for	NULL
these	NULL
same	NULL
two	NULL
cell	NULL
lines	NULL
(	NULL
33	NULL
)	NULL
.	NULL

LPS	NULL
concentrations	NULL
on	NULL
the	NULL
order	NULL
of	NULL
100	NULL
ng/ml	NULL
were	NULL
required	NULL
to	NULL
induce	NULL
surface	NULL
expression	NULL
of	NULL
IgM	NULL
in	NULL
CD14-negative	NULL
cells	NULL
(	NULL
via	NULL
the	NULL
CD14-independent	NULL
pathway	NULL
)	NULL
,	NULL
whereas	NULL
a	NULL
low	NULL
dose	NULL
of	NULL
LPS	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

readily	NULL
induced	NULL
surface	NULL
IgM	NULL
expression	NULL
by	NULL
hCD14-transfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
NF-kB	NULL
results	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
,	NULL
surface	NULL
IgM	NULL
was	NULL
not	NULL
induced	NULL
in	NULL
either	NULL
cell	NULL
line	NULL
following	NULL
a	NULL
24-h	NULL
incubation	NULL
with	NULL
the	NULL
OspA	NULL
or	NULL
Tpp17	NULL
lipopeptide	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Analogous	NULL
results	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
surface	NULL
IgM	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
were	NULL
obtained	NULL
when	NULL
CD14-negative	NULL
and	NULL
hCD14-transfected	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
32	NULL
nM	NULL
(	NULL
ca	NULL
.	NULL

1	NULL
mg/m	NULL
!	NULL
)	NULL

native	NULL
OspA	NULL
.	NULL

Cells	NULL
of	NULL
the	NULL
monocyte-macrophage	NULL
lineage	NULL
,	NULL
which	NULL
are	NULL
abundant	NULL
in	NULL
syphilitic	NULL
lesions	NULL
(	NULL
28	NULL
,	NULL
35	NULL
)	NULL
,	NULL
are	NULL
important	NULL
targets	NULL
of	NULL
HIV	NULL
infection	NULL
(	NULL
24	NULL
,	NULL
54	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
binding	NULL
of	NULL
NF-kB	NULL
to	NULL
the	NULL
HIV	NULL
promoter	NULL
is	NULL
associated	NULL
with	NULL
enhanced	NULL
HIV	NULL
gene	NULL
expression	NULL
and	NULL
replication	NULL
of	NULL
virus	NULL
within	NULL
infected	NULL
monocytes	NULL
(	NULL
4	NULL
,	NULL
46	NULL
,	NULL
54	NULL
)	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
7.	NULL
pallidum	NULL
lipoprotein	NULL
analogs	NULL
induce	NULL
the	NULL
translocation	NULL
of	NULL
NF-kB	NULL
,	NULL
coupled	NULL
with	NULL
the	NULL
association	NULL
between	NULL
syphilitic	NULL
genital	NULL
ulcers	NULL
and	NULL
transmission	NULL
of	NULL
HIV	NULL
(	NULL
26	NULL
,	NULL
38	NULL
,	NULL
69	NULL
)	NULL
,	NULL
prompted	NULL
us	NULL
to	NULL
examine	NULL
whether	NULL
treponemal	NULL
lipopeptides	NULL
could	NULL
stimulate	NULL
HIV	NULL
replication	NULL
.	NULL

U1	NULL
monocytoid	NULL
cells	NULL
chronically	NULL
infected	NULL
with	NULL
HIV-1	NULL
were	NULL
incubated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
either	NULL
LPS	NULL
,	NULL
lipopeptide	NULL
Tpp47	NULL
or	NULL
Tpp17	NULL
,	NULL
or	NULL
the	NULL
corresponding	NULL
nonacylated	NULL
peptide	NULL
control	NULL
.	NULL

LPS	NULL
,	NULL
which	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
HIV	NULL
gene	NULL
expression	NULL
via	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
46	NULL
)	NULL
,	NULL
provided	NULL
the	NULL
positive	NULL
control	NULL
for	NULL
these	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

As	NULL
with	NULL
LPS	NULL
,	NULL
the	NULL
treponemal	NULL
lipopeptides	NULL
,	NULL
but	NULL
not	NULL
their	NULL
nonacylated	NULL
counterparts	NULL
,	NULL
induced	NULL
HIV-1	NULL
replication	NULL
as	NULL
assessed	NULL
by	NULL
detection	NULL
of	NULL
the	NULL
p24	NULL
antigen	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

This	NULL
effect	NULL
likely	NULL
was	NULL
not	NULL
due	NULL
to	NULL
secondary	NULL
autocrine	NULL
effects	NULL
from	NULL
elicited	NULL
cyto-kines	NULL
,	NULL
inasmuch	NULL
as	NULL
U937	NULL
cells	NULL
,	NULL
the	NULL
parental	NULL
cell	NULL
line	NULL
of	NULL
U1	NULL
,	NULL
first	NULL
must	NULL
be	NULL
induced	NULL
to	NULL
differentiate	NULL
with	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
before	NULL
they	NULL
can	NULL
produce	NULL
IL-1	NULL
B	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
at	NULL
least	NULL
in	NULL
response	NULL
to	NULL
LPS	NULL
stimulation	NULL
)	NULL
(	NULL
21	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
absence	NULL
of	NULL
classical	NULL
endotoxin	NULL
in	NULL
both	NULL
T.	NULL
pallidum	NULL
and	NULL
B.	NULL
burgdorferi	NULL
has	NULL
provided	NULL
impetus	NULL
for	NULL
identifying	NULL
the	NULL
constituents	NULL
of	NULL
these	NULL
two	NULL
pathogens	NULL
which	NULL
elicit	NULL
inflammatory	NULL
responses	NULL
.	NULL

Such	NULL
studies	NULL
,	NULL
however	NULL
,	NULL
have	NULL
been	NULL
impeded	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
systems	NULL
for	NULL
genetically	NULL
manipulating	NULL
these	NULL
two	NULL
spirochetal	NULL
pathogens	NULL
.	NULL

Building	NULL
upon	NULL
the	NULL
experimental	NULL
strategies	NULL
pioneered	NULL
by	NULL
Bessler	NULL
and	NULL
colleagues	NULL
in	NULL
their	NULL
studies	NULL
of	NULL
murein	NULL
lipoprotein	NULL
of	NULL
E.	NULL
coli	NULL
(	NULL
22	NULL
,	NULL
25	NULL
)	NULL
,	NULL
investigators	NULL
of	NULL
spirochetal	NULL
disease	NULL
immunopathogenesis	NULL
have	NULL
utilized	NULL
a	NULL
number	NULL
of	NULL
tissue	NULL
culture	NULL
systems	NULL
to	NULL
demonstrate	NULL
that	NULL
various	NULL
7.	NULL
pallidum	NULL
and	NULL
B.	NULL
burgdorferi	NULL
lipoproteins	NULL
and	NULL
synthetic	NULL
analogs	NULL
have	NULL
comparable	NULL
proinflammatory	NULL
properties	NULL
(	NULL
2	NULL
,	NULL
14	NULL
,	NULL
36	NULL
,	NULL
37	NULL
,	NULL
43	NULL
,	NULL
50	NULL
,	NULL
51	NULL
,	NULL
53	NULL
,	NULL
58	NULL
,	NULL
63	NULL
,	NULL
71	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
following	NULL
intradermal	NULL
injection	NULL
into	NULL
mice	NULL
and	NULL
rabbits	NULL
,	NULL
lipopeptides	NULL
derived	NULL
from	NULL
both	NULL
borrelial	NULL
and	NULL
treponemal	NULL
lipoproteins	NULL
elicited	NULL
histopathological	NULL
responses	NULL
which	NULL
resembled	NULL
those	NULL
in	NULL
syphilis	NULL
and	NULL
Lyme	NULL
disease	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Taken	NULL
to-gether	NULL
,	NULL
these	NULL
observations	NULL
constitute	NULL
a	NULL
strong	NULL
body	NULL
of	NULL
evidence	NULL
that	NULL
spirochetal	NULL
lipoproteins	NULL
are	NULL
key	NULL
inflammatory	NULL
mediators	NULL
in	NULL
syphilis	NULL
and	NULL
Lyme	NULL
disease	NULL
and	NULL
,	NULL
as	NULL
such	NULL
,	NULL
should	NULL
be	NULL
considered	NULL
among	NULL
the	NULL
components	NULL
of	NULL
bacterial	NULL
cell	NULL
envelopes	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
LPS	NULL
,	NULL
which	NULL
possess	NULL
immunostimulatory	NULL
activities	NULL
.	NULL

A	NULL
principal	NULL
goal	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
obtain	NULL
further	NULL
support	NULL
for	NULL
the	NULL
proposal	NULL
that	NULL
LPS	NULL
and	NULL
spirochetal	NULL
lipoproteins	NULL
and	NULL
lipopeptides	NULL
initiate	NULL
immune	NULL
cell	NULL
activation	NULL
via	NULL
different	NULL
Vou	NULL
.	NULL

64	NULL
,	NULL
1996	NULL
MONOCYTE	NULL
ACTIVATION	NULL
BY	NULL
LIPOPROTEINS	NULL
AND	NULL
LIPOPEPTIDES	NULL
3849	NULL
Unstim	NULL
.	NULL
'	NULL

|LPS	NULL
+	NULL
|LPS	NULL
'	NULL
|OspA-L	NULL
+	NULL
|OspA-L	NULL
'	NULL
|OspA	NULL
17L	NULL
+	NULL
|17ZL	NULL
17	NULL
P	NULL
B	NULL
B	NULL
702/3	NULL
(	NULL
CD14	NULL
)	NULL
702/3	NULL
(	NULL
CD14t	NULL
)	NULL
g	NULL
”	NULL
LPS	NULL
10GNGAML	NULL
§	NULL
'	NULL
LPS	NULL
1900NGAML	NULL
LPS	NULL
10NGAML	NULL
LPS	NULL
10NGAML	NULL
UNSTIMULATED	NULL
UNSTIMULATED	NULL
17	NULL
10UM	NULL
17	NULL
10UM	NULL
17L	NULL
19UM	NULL
$	NULL
17L	NULL
19UM	NULL
OSP	NULL
A	NULL
10UM	NULL
OSP	NULL
A	NULL
10UM	NULL
OSP	NULL
A-L	NULL
10UM	NULL
OSP	NULL
A-L	NULL
10UM	NULL
@	NULL
C	NULL
LPS	NULL
(	NULL
10ng/ml	NULL
8	NULL
|	NULL
g/m	NULL
!	NULL

1	NULL
)	NULL
|	NULL
LPS	NULL
(	NULL
100ng/m	NULL
!	NULL
)	NULL

.	NULL

o	NULL
LPS	NULL
(	NULL
10ng/m1	NULL
)	NULL
£	NULL
.	NULL

0	NULL
fs	NULL
``	NULL
LPS	NULL
(	NULL
100ng/m|1	NULL
)	NULL
E	NULL
13	NULL
Z	NULL
Eli-3°	NULL
M3	NULL
e	NULL
H	NULL
'	NULL
l	NULL
'	NULL
é	NULL
“	NULL
”	NULL
15°	NULL
``	NULL
o	NULL
``	NULL
1331	NULL
Po	NULL
”	NULL
nl'é2	NULL
l	NULL
Hui-Q3	NULL
i	NULL
”	NULL
HM	NULL
``	NULL
Fluorescence	NULL
Fluorescence	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Spirochetal	NULL
synthetic	NULL
lipopeptides	NULL
fail	NULL
to	NULL
activate	NULL
hCD14-transfected	NULL
70Z/3	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
in	NULL
hCD14-transfected	NULL
702	NULL
,	NULL
/3	NULL
cells	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
a	NULL
10	NULL
wM	NULL
concentration	NULL
of	NULL
a	NULL
lipopeptide	NULL
corresponding	NULL
to	NULL
either	NULL
OspA	NULL
(	NULL
OspA-L	NULL
)	NULL
or	NULL
Tpp17	NULL
(	NULL
17L	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
PB	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
induced	NULL
by	NULL
LPS	NULL
(	NULL
10	NULL
nM	NULL
;	NULL
40	NULL
ng/m	NULL
!	NULL
)	NULL

is	NULL
indicated	NULL
by	NULL
the	NULL
arrowhead	NULL
.	NULL

Nonacylated	NULL
hexapeptides	NULL
corresponding	NULL
to	NULL
OspA	NULL
(	NULL
lane	NULL
OspA	NULL
)	NULL
and	NULL
Tpp17	NULL
(	NULL
lane	NULL
17	NULL
)	NULL
were	NULL
included	NULL
as	NULL
negative	NULL
controls	NULL
.	NULL

Unstim	NULL
.	NULL

,	NULL
unstimulated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
surface	NULL
IgM	NULL
expression	NULL
in	NULL
untransfected	NULL
(	NULL
CD14	NULL
)	NULL
or	NULL
hCD14-transfected	NULL
(	NULL
CD14	NULL
*	NULL
)	NULL
70Z	NULL
,	NULL
/3	NULL
cells	NULL
following	NULL
incubation	NULL
for	NULL
24	NULL
h	NULL
with	NULL
either	NULL
the	NULL
same	NULL
two	NULL
lipopeptides	NULL
,	NULL
the	NULL
corresponding	NULL
nonacylated	NULL
peptide	NULL
controls	NULL
,	NULL
or	NULL
a	NULL
high	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
low	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

dose	NULL
of	NULL
LPS	NULL
.	NULL

All	NULL
of	NULL
the	NULL
samples	NULL
tested	NULL
are	NULL
listed	NULL
in	NULL
the	NULL
upper	NULL
right-hand	NULL
corner	NULL
of	NULL
each	NULL
graph	NULL
;	NULL
for	NULL
simplicity	NULL
,	NULL
only	NULL
the	NULL
curves	NULL
corresponding	NULL
to	NULL
the	NULL
LPS	NULL
samples	NULL
are	NULL
labeled	NULL
,	NULL
inasmuch	NULL
as	NULL
all	NULL
of	NULL
the	NULL
other	NULL
samples	NULL
yielded	NULL
negative	NULL
results	NULL
for	NULL
both	NULL
CD14~7	NULL
and	NULL
CD14*	NULL
cells	NULL
.	NULL

Surface	NULL
IgM	NULL
expression	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
rightward	NULL
curve	NULL
shift	NULL
(	NULL
left	NULL
graph	NULL
,	NULL
LPS	NULL
at	NULL
100	NULL
ng/ml	NULL
;	NULL
right	NULL
graph	NULL
,	NULL
LPS	NULL
at	NULL
10	NULL
and	NULL
100	NULL
ng/ml	NULL
)	NULL
.	NULL

The	NULL
slight	NULL
rightward	NULL
shift	NULL
in	NULL
one	NULL
of	NULL
the	NULL
other	NULL
histograms	NULL
(	NULL
OspA-L	NULL
;	NULL
unlabeled	NULL
)	NULL
was	NULL
not	NULL
statistically	NULL
significant	NULL
from	NULL
unstimulated	NULL
cultures	NULL
.	NULL

UM	NULL
,	NULL
micromolar	NULL
.	NULL

3850	NULL
NORGARD	NULL
ET	NULL
AL	NULL
.	NULL

702/3	NULL
(	NULL
CD14	NULL
)	NULL
seo	NULL
LPS	NULL
1GNGAML	NULL
OSP	NULL
A	NULL
-	NULL
10uM	NULL
OSP	NULL
A-L	NULL
10uM	NULL
ROSP	NULL
A	NULL
-	NULL
32nM	NULL
NOSP	NULL
A	NULL
-	NULL
32nM	NULL
LPS	NULL
(	NULL
10ng/mi1	NULL
)	NULL
Number	NULL
of	NULL
cells	NULL
Fluorescence	NULL
LPS	NULL
100NGAML	NULL
UNST	NULL
IMULATED	NULL
LPS	NULL
(	NULL
100ng/mi	NULL
)	NULL
InFECT	NULL
.	NULL

ImnmUN	NULL
.	NULL

70Z2/3	NULL
(	NULL
CD14t	NULL
)	NULL
®	NULL
&	NULL
|	NULL
LPS	NULL
LPS	NULL
10NG-ML	NULL
UNST	NULL
IMULATED	NULL
OSP	NULL
A	NULL
_	NULL
10.4	NULL
OSP	NULL
A-L	NULL
1ouM	NULL
ROSP	NULL
A	NULL
-	NULL
s2nM	NULL
NOSP	NULL
A	NULL
|	NULL
32nM	NULL
LPS	NULL
LPS	NULL
(	NULL
10ng/m|	NULL
)	NULL
102	NULL
Fluorescence	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
surface	NULL
IgM	NULL
expression	NULL
in	NULL
untransfected	NULL
(	NULL
CD14	NULL
)	NULL
or	NULL
hCD14-transfected	NULL
(	NULL
CD14	NULL
*	NULL
)	NULL
70Z/3	NULL
cells	NULL
following	NULL
incubation	NULL
for	NULL
24	NULL
h	NULL
with	NULL
native	NULL
OspA	NULL
(	NULL
32	NULL
nM	NULL
;	NULL
ca	NULL
.	NULL

1	NULL
pg/ml	NULL
)	NULL
,	NULL
an	NULL
equivalent	NULL
concentration	NULL
of	NULL
recombinant	NULL
(	NULL
nonacylated	NULL
)	NULL
OspA	NULL
,	NULL
and	NULL
high	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
low	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

doses	NULL
of	NULL
LPS	NULL
.	NULL

OspA	NULL
lipopeptide	NULL
and	NULL
nonacylated	NULL
peptide	NULL
(	NULL
each	NULL
at	NULL
10	NULL
M	NULL
)	NULL
also	NULL
were	NULL
included	NULL
for	NULL
comparison	NULL
with	NULL
native	NULL
OspA	NULL
.	NULL

As	NULL
in	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
surface	NULL
expression	NULL
of	NULL
IgM	NULL
in	NULL
response	NULL
to	NULL
LPS	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
rightward	NULL
shift	NULL
.	NULL

cell	NULL
surface	NULL
events	NULL
.	NULL

The	NULL
most	NULL
important	NULL
prior	NULL
evidence	NULL
for	NULL
this	NULL
was	NULL
the	NULL
observation	NULL
that	NULL
synthetic	NULL
lipoproteins	NULL
and	NULL
lipoprotein	NULL
analogs	NULL
activated	NULL
peritoneal	NULL
macrophages	NULL
from	NULL
LPS-nonre-sponsive	NULL
(	NULL
C3H/HeJ	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
LPS-responsive	NULL
(	NULL
C3H/HeN	NULL
)	NULL
,	NULL
mice	NULL
(	NULL
50	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Because	NULL
there	NULL
is	NULL
strong	NULL
evidence	NULL
that	NULL
C3H/HeJ	NULL
macrophages	NULL
express	NULL
normal	NULL
levels	NULL
of	NULL
CD14	NULL
(	NULL
13	NULL
)	NULL
,	NULL
our	NULL
results	NULL
K	NULL
K	NULL
o	NULL
m	NULL
o	NULL
to	NULL
ng/ml	NULL
p24	NULL
Ag	NULL
LPS	NULL
Neg	NULL
.	NULL

47	NULL
47L	NULL
h	NULL
17L	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Synthetic	NULL
7.	NULL
pallidum	NULL
lipopeptides	NULL
induce	NULL
HIV-1	NULL
in	NULL
U1	NULL
cells	NULL
.	NULL

U1	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
either	NULL
LPS	NULL
(	NULL
200	NULL
ng/ml	NULL
)	NULL
,	NULL
lipopeptides	NULL
representative	NULL
of	NULL
Tpp47	NULL
(	NULL
471	NULL
)	NULL
and	NULL
Tpp17	NULL
(	NULL
171	NULL
)	NULL
(	NULL
30	NULL
M	NULL
)	NULL
,	NULL
or	NULL
corresponding	NULL
nonacylated	NULL
peptide	NULL
(	NULL
bars	NULL
47	NULL
and	NULL
17	NULL
)	NULL
controls	NULL
(	NULL
30	NULL
M	NULL
)	NULL
.	NULL

Culture	NULL
supernatants	NULL
were	NULL
assayed	NULL
for	NULL
HIV-1	NULL
by	NULL
quantitative	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
for	NULL
p24	NULL
antigen	NULL
(	NULL
Ag	NULL
)	NULL
.	NULL

Data	NULL
from	NULL
three	NULL
trials	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
average	NULL
+	NULL
the	NULL
standard	NULL
deviations	NULL
.	NULL

Levels	NULL
of	NULL
p24	NULL
antigen	NULL
only	NULL
from	NULL
cultures	NULL
treated	NULL
with	NULL
LPS	NULL
(	NULL
P	NULL
=	NULL
0.003	NULL
)	NULL
,	NULL
47L	NULL
(	NULL
P	NULL
=	NULL
0.005	NULL
)	NULL
,	NULL
and	NULL
17L	NULL
(	NULL
P	NULL
=	NULL
0.002	NULL
)	NULL
were	NULL
significantly	NULL
different	NULL
(	NULL
asterisks	NULL
)	NULL
from	NULL
those	NULL
of	NULL
unstimulated	NULL
(	NULL
Neg	NULL
.	NULL
)	NULL

cultures	NULL
(	NULL
Fisher	NULL
's	NULL
least	NULL
significant	NULL
difference	NULL
)	NULL
.	NULL

implied	NULL
that	NULL
the	NULL
CD14-dependent	NULL
pathway	NULL
utilized	NULL
by	NULL
LPS	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
cell	NULL
activation	NULL
by	NULL
spirochetal	NULL
lipoproteins	NULL
and	NULL
lipopeptides	NULL
.	NULL

Here	NULL
we	NULL
showed	NULL
that	NULL
hCD14	NULL
expression	NULL
,	NULL
which	NULL
conferred	NULL
LPS	NULL
sensitivity	NULL
on	NULL
70Z/3	NULL
cells	NULL
,	NULL
did	NULL
not	NULL
impart	NULL
responsiveness	NULL
to	NULL
OspA	NULL
or	NULL
to	NULL
two	NULL
different	NULL
spirochetal	NULL
lipopeptides	NULL
.	NULL

These	NULL
results	NULL
were	NULL
buttressed	NULL
by	NULL
our	NULL
use	NULL
of	NULL
two	NULL
different	NULL
indicators	NULL
of	NULL
cell	NULL
activation	NULL
,	NULL
NF-xB	NULL
translocation	NULL
and	NULL
surface	NULL
IgM	NULL
expression	NULL
,	NULL
representative	NULL
of	NULL
early	NULL
signaling	NULL
events	NULL
and	NULL
a	NULL
phe-notypic	NULL
endpoint	NULL
following	NULL
prolonged	NULL
stimulation	NULL
with	NULL
these	NULL
compounds	NULL
,	NULL
respectively	NULL
.	NULL

While	NULL
our	NULL
results	NULL
are	NULL
most	NULL
easily	NULL
explained	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
CD14	NULL
involvement	NULL
in	NULL
lipoprotein-lipopeptide-mediated	NULL
cell	NULL
activation	NULL
,	NULL
our	NULL
experiments	NULL
have	NULL
not	NULL
eliminated	NULL
the	NULL
possibility	NULL
that	NULL
these	NULL
spirochetal	NULL
constituents	NULL
utilize	NULL
an	NULL
alternative	NULL
,	NULL
but	NULL
undescribed	NULL
,	NULL
CD14-dependent	NULL
pathway	NULL
.	NULL

Experiments	NULL
with	NULL
macrophages	NULL
from	NULL
CD14-deficient	NULL
mice	NULL
should	NULL
be	NULL
instrumental	NULL
in	NULL
resolving	NULL
this	NULL
issue	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
highly	NULL
similar	NULL
cytokine	NULL
profiles	NULL
elicited	NULL
in	NULL
macrophages	NULL
by	NULL
spirochetal	NULL
lipoproteins-lipopeptides	NULL
and	NULL
LPS	NULL
(	NULL
36	NULL
,	NULL
51	NULL
,	NULL
63	NULL
,	NULL
65	NULL
)	NULL
suggested	NULL
that	NULL
despite	NULL
the	NULL
differences	NULL
in	NULL
initial	NULL
signaling	NULL
events	NULL
,	NULL
the	NULL
two	NULL
pathways	NULL
eventually	NULL
overlap	NULL
or	NULL
possibly	NULL
con-verge	NULL
.	NULL

To	NULL
investigate	NULL
this	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
study	NULL
translocation	NULL
of	NULL
the	NULL
transcriptional	NULL
activator	NULL
NF-kB	NULL
,	NULL
a	NULL
critical	NULL
distal	NULL
event	NULL
in	NULL
the	NULL
pathway	NULL
(	NULL
s	NULL
)	NULL
by	NULL
which	NULL
LPS	NULL
induces	NULL
cytokine	NULL
production	NULL
(	NULL
41	NULL
,	NULL
54	NULL
)	NULL
.	NULL

Like	NULL
LPS	NULL
,	NULL
spirochetal	NULL
lipoproteins	NULL
and	NULL
lipopeptides	NULL
induced	NULL
NF-kB	NULL
;	NULL
moreover	NULL
,	NULL
the	NULL
relatively	NULL
rapid	NULL
time	NULL
course	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
was	NULL
compatible	NULL
with	NULL
a	NULL
direct	NULL
effect	NULL
(	NULL
as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
LPS	NULL
)	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
indirect	NULL
,	NULL
autocrine	NULL
stimulation	NULL
by	NULL
elicited	NULL
cytokines	NULL
.	NULL

There	NULL
is	NULL
considerable	NULL
evidence	NULL
for	NULL
the	NULL
involvement	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
events	NULL
(	NULL
particularly	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
)	NULL
in	NULL
LPS	NULL
signaling	NULL
(	NULL
15	NULL
,	NULL
18	NULL
,	NULL
19	NULL
)	NULL
;	NULL
some	NULL
evidence	NULL
also	NULL
exists	NULL
for	NULL
the	NULL
involvement	NULL
of	NULL
similar	NULL
phosphorylation	NULL
events	NULL
in	NULL
the	NULL
responses	NULL
to	NULL
both	NULL
LPS	NULL
and	NULL
bacterial	NULL
lipoproteins	NULL
or	NULL
lipopeptides	NULL
(	NULL
15	NULL
,	NULL
44	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
stage	NULL
is	NULL
set	NULL
VoL	NULL
.	NULL

64	NULL
,	NULL
1996	NULL
for	NULL
a	NULL
detailed	NULL
comparative	NULL
analysis	NULL
of	NULL
upstream	NULL
events	NULL
in	NULL
the	NULL
LPS	NULL
and	NULL
lipoprotein-lipopeptide	NULL
signaling	NULL
pathways	NULL
to	NULL
identify	NULL
points	NULL
of	NULL
convergence	NULL
and/or	NULL
overlap	NULL
.	NULL

Epidemiological	NULL
studies	NULL
have	NULL
implicated	NULL
syphilis	NULL
and	NULL
other	NULL
genital	NULL
ulcer	NULL
diseases	NULL
as	NULL
cofactors	NULL
in	NULL
the	NULL
transmission	NULL
of	NULL
HIV	NULL
(	NULL
26	NULL
,	NULL
27	NULL
,	NULL
61	NULL
,	NULL
69	NULL
)	NULL
.	NULL

At	NULL
least	NULL
two	NULL
features	NULL
of	NULL
chancres	NULL
are	NULL
likely	NULL
to	NULL
contribute	NULL
to	NULL
this	NULL
phenomenon	NULL
.	NULL

First	NULL
,	NULL
the	NULL
breach	NULL
in	NULL
the	NULL
protective	NULL
epithelial	NULL
barrier	NULL
would	NULL
either	NULL
expose	NULL
HIV-infected	NULL
body	NULL
fluids	NULL
or	NULL
create	NULL
a	NULL
portal	NULL
of	NULL
entry	NULL
in	NULL
a	NULL
non-HIV-infected	NULL
individual	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
influx	NULL
of	NULL
large	NULL
numbers	NULL
of	NULL
macrophages	NULL
and	NULL
T	NULL
cells	NULL
into	NULL
syphilitic	NULL
ulcers	NULL
(	NULL
35	NULL
)	NULL
could	NULL
facilitate	NULL
HIV	NULL
acquisition	NULL
by	NULL
providing	NULL
an	NULL
environment	NULL
rich	NULL
in	NULL
immune	NULL
cells	NULL
expressing	NULL
receptors	NULL
for	NULL
HIV	NULL
.	NULL

By	NULL
activating	NULL
immune	NULL
cells	NULL
at	NULL
such	NULL
local	NULL
sites	NULL
of	NULL
infection	NULL
,	NULL
it	NULL
also	NULL
is	NULL
plausible	NULL
that	NULL
T.	NULL
pallidum	NULL
provides	NULL
an	NULL
antigenic	NULL
stimulus	NULL
which	NULL
``	NULL
drives	NULL
``	NULL
HIV	NULL
replication	NULL
within	NULL
these	NULL
lesions	NULL
,	NULL
thereby	NULL
promoting	NULL
transmission	NULL
.	NULL

The	NULL
proinflammatory	NULL
activities	NULL
of	NULL
the	NULL
treponemal	NULL
lipoproteins	NULL
could	NULL
amplify	NULL
this	NULL
process	NULL
both	NULL
by	NULL
directly	NULL
inducing	NULL
NF-kB	NULL
in	NULL
macrophages	NULL
and	NULL
by	NULL
stimulating	NULL
macrophages	NULL
to	NULL
produce	NULL
cy-tokines	NULL
,	NULL
such	NULL
as	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
,	NULL
IL-1B	NULL
,	NULL
and	NULL
IL-6	NULL
,	NULL
which	NULL
enhance	NULL
HIV	NULL
replication	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
because	NULL
syphilis	NULL
,	NULL
unlike	NULL
other	NULL
genital	NULL
ulcer	NULL
diseases	NULL
,	NULL
is	NULL
almost	NULL
always	NULL
a	NULL
disseminated	NULL
infection	NULL
,	NULL
the	NULL
possibility	NULL
exists	NULL
that	NULL
syphilitic	NULL
infection	NULL
,	NULL
particularly	NULL
in	NULL
the	NULL
secondary	NULL
stage	NULL
,	NULL
may	NULL
be	NULL
capable	NULL
of	NULL
stimulating	NULL
systemic	NULL
HIV	NULL
replication	NULL
,	NULL
thereby	NULL
accelerating	NULL
the	NULL
course	NULL
of	NULL
HIV	NULL
disease	NULL
.	NULL

Work	NULL
by	NULL
us	NULL
(	NULL
2	NULL
,	NULL
14	NULL
,	NULL
50	NULL
,	NULL
51	NULL
,	NULL
53	NULL
)	NULL
and	NULL
by	NULL
others	NULL
(	NULL
22	NULL
,	NULL
25	NULL
,	NULL
36	NULL
,	NULL
37	NULL
,	NULL
58	NULL
,	NULL
63	NULL
,	NULL
71	NULL
)	NULL
has	NULL
shown	NULL
that	NULL
a	NULL
variety	NULL
of	NULL
bacterial	NULL
lipoproteins	NULL
and	NULL
lipopeptides	NULL
can	NULL
activate	NULL
immune	NULL
effector	NULL
cells	NULL
.	NULL

While	NULL
this	NULL
common	NULL
biological	NULL
property	NULL
presumably	NULL
reflects	NULL
a	NULL
shared	NULL
biochemical	NULL
structure	NULL
or	NULL
configuration	NULL
,	NULL
it	NULL
is	NULL
noteworthy	NULL
that	NULL
tri-palmitoyl-§-glycerylcysteine	NULL
,	NULL
the	NULL
only	NULL
moiety	NULL
common	NULL
to	NULL
both	NULL
lipoproteins	NULL
and	NULL
synthetic	NULL
analogs	NULL
,	NULL
lacks	NULL
proinflammatory	NULL
activity	NULL
(	NULL
9	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Acyl	NULL
modification	NULL
via	NULL
this	NULL
configuration	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
appears	NULL
to	NULL
be	NULL
necessary	NULL
,	NULL
although	NULL
not	NULL
sufficient	NULL
,	NULL
for	NULL
biological	NULL
activity	NULL
of	NULL
this	NULL
class	NULL
of	NULL
compounds	NULL
(	NULL
9	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
covalently	NULL
bound	NULL
lipids	NULL
provide	NULL
membrane	NULL
anchors	NULL
for	NULL
the	NULL
native	NULL
spirochetal	NULL
proteins	NULL
(	NULL
29	NULL
,	NULL
39	NULL
)	NULL
,	NULL
we	NULL
have	NULL
proposed	NULL
that	NULL
the	NULL
lipids	NULL
also	NULL
promote	NULL
insertion	NULL
of	NULL
the	NULL
proteins	NULL
and/or	NULL
peptides	NULL
into	NULL
eukaryotic	NULL
cell	NULL
membranes	NULL
,	NULL
where	NULL
they	NULL
interact	NULL
with	NULL
one	NULL
or	NULL
more	NULL
unidentified	NULL
components	NULL
of	NULL
the	NULL
signaling	NULL
apparatus	NULL
.	NULL

While	NULL
it	NULL
remains	NULL
conjectural	NULL
(	NULL
and	NULL
somewhat	NULL
para-doxical	NULL
)	NULL
that	NULL
these	NULL
diverse	NULL
compounds	NULL
may	NULL
initiate	NULL
cell	NULL
activation	NULL
via	NULL
specific	NULL
receptor-ligand-type	NULL
interactions	NULL
,	NULL
the	NULL
polymorphic	NULL
nature	NULL
of	NULL
this	NULL
phenomenon	NULL
has	NULL
important	NULL
implications	NULL
for	NULL
Lyme	NULL
disease	NULL
pathogenesis	NULL
.	NULL

There	NULL
is	NULL
a	NULL
substantial	NULL
body	NULL
of	NULL
evidence	NULL
that	NULL
B.	NULL
burgdorferi	NULL
does	NULL
not	NULL
express	NULL
OspA	NULL
and	NULL
OspB	NULL
within	NULL
mammalian	NULL
hosts	NULL
(	NULL
40	NULL
,	NULL
57	NULL
,	NULL
62	NULL
)	NULL
and	NULL
that	NULL
other	NULL
,	NULL
antigeni-cally	NULL
unrelated	NULL
proteins	NULL
are	NULL
expressed	NULL
following	NULL
tick	NULL
transmission	NULL
(	NULL
1	NULL
,	NULL
12	NULL
,	NULL
40	NULL
,	NULL
57	NULL
,	NULL
62	NULL
,	NULL
68	NULL
)	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
proinflammatory	NULL
activity	NULL
is	NULL
a	NULL
``	NULL
generic	NULL
``	NULL
property	NULL
of	NULL
spirochetal	NULL
lipoproteins	NULL
raises	NULL
the	NULL
intriguing	NULL
possibility	NULL
that	NULL
lipoproteins	NULL
unrelated	NULL
to	NULL
OspA	NULL
or	NULL
OspB	NULL
which	NULL
are	NULL
expressed	NULL
exclusively	NULL
during	NULL
the	NULL
course	NULL
of	NULL
infection	NULL
can	NULL
promote	NULL
the	NULL
inflammatory	NULL
processes	NULL
that	NULL
engender	NULL
clinical	NULL
manifestations	NULL
in	NULL
chronic	NULL
Lyme	NULL
disease	NULL
.	NULL

This	NULL
contention	NULL
can	NULL
be	NULL
evaluated	NULL
by	NULL
examining	NULL
the	NULL
proinflammatory	NULL
properties	NULL
of	NULL
borrelial	NULL
lipoproteins	NULL
expressed	NULL
exclusively	NULL
during	NULL
the	NULL
mammalian	NULL
phase	NULL
of	NULL
the	NULL
spirochete	NULL
life	NULL
cycle	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Lynn	NULL
DeOgny-Mayfield	NULL
and	NULL
Clive	NULL
Slaughter	NULL
for	NULL
lipopeptide	NULL
synthesis	NULL
,	NULL
Jorge	NULL
Benach	NULL
for	NULL
providing	NULL
B.	NULL
burgdorferi	NULL
TII-EV	NULL
,	NULL
Richard	NULL
Ulevitch	NULL
for	NULL
providing	NULL
70Z/3	NULL
cell	NULL
lines	NULL
,	NULL
Anne	NULL
Snider	NULL
for	NULL
performing	NULL
p24	NULL
antigen	NULL
assays	NULL
,	NULL
and	NULL
Robert	NULL
Munford	NULL
,	NULL
Richard	NULL
Kitchens	NULL
,	NULL
and	NULL
Richard	NULL
Gaynor	NULL
for	NULL
many	NULL
helpful	NULL
discussions	NULL
.	NULL

MONOCYTE	NULL
ACTIVATION	NULL
BY	NULL
LIPOPROTEINS	NULL
AND	NULL
LIPOPEPTIDES	NULL
3851	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
AI-16692	NULL
,	NULL
Al-29735	NULL
,	NULL
AI-26756	NULL
,	NULL
and	NULL
AI-38894	NULL
from	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
by	NULL
grant	NULL
1-0940	NULL
from	NULL
the	NULL
Robert	NULL
A.	NULL
Welch	NULL
Foundation	NULL
,	NULL
and	NULL
by	NULL
grant-in-aid	NULL
91015470	NULL
from	NULL
the	NULL
American	NULL
Heart	NULL
Association	NULL
.	NULL

J.D.R	NULL
.	NULL

was	NULL
a	NULL
recipient	NULL
of	NULL
an	NULL
American	NULL
Heart	NULL
Association	NULL
Established	NULL
Investigatorship	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Akins	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
S.	NULL
F.	NULL
Porcella	NULL
,	NULL
T.	NULL
G.	NULL
Popova	NULL
,	NULL
D.	NULL
Shevchenko	NULL
,	NULL
M.	NULL
Li	NULL
,	NULL
M.	NULL
V.	NULL
Norgard	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Radolf	NULL
.	NULL

1995	NULL
.	NULL

Evidence	NULL
for	NULL
in	NULL
vivo	NULL
but	NULL
not	NULL
in	NULL
vitro	NULL
expression	NULL
of	NULL
a	NULL
Borrelia	NULL
burgdorferi	NULL
outer	NULL
surface	NULL
protein	NULL
F	NULL
(	NULL
OspF	NULL
)	NULL
homo-logue	NULL
.	NULL

Mol	NULL
.	NULL

Microbiol	NULL
.	NULL

18:507-520	NULL
.	NULL

2	NULL
.	NULL

Akins	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
B.	NULL
K.	NULL
Purcell	NULL
,	NULL
M.	NULL
Mitra	NULL
,	NULL
M.	NULL
V.	NULL
Norgard	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Radolf	NULL
.	NULL

1993	NULL
.	NULL

Lipid	NULL
modification	NULL
of	NULL
the	NULL
17-kilodalton	NULL
membrane	NULL
immunogen	NULL
of	NULL
Treponema	NULL
pallidum	NULL
determines	NULL
macrophage	NULL
activation	NULL
as	NULL
well	NULL
as	NULL
amphiphilicity	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

61:1202-1210	NULL
.	NULL

3	NULL
.	NULL

Auwerx	NULL
,	NULL
J	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
human	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
THP-1	NULL
:	NULL
a	NULL
multifacetted	NULL
model	NULL
for	NULL
the	NULL
study	NULL
of	NULL
monocyte-macrophage	NULL
differentiation	NULL
.	NULL

Experientia	NULL
47:22-31	NULL
.	NULL

4	NULL
.	NULL

Bachelerie	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
F.	NULL
Arenzana-Seisdedos	NULL
,	NULL
and	NULL
J.-L.	NULL
Virelizier	NULL
.	NULL

1991	NULL
.	NULL

HIV	NULL
enhancer	NULL
activity	NULL
perpetuated	NULL
by	NULL
NF-kappaB	NULL
induction	NULL
on	NULL
infection	NULL
of	NULL
monocytes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
350:709-712	NULL
.	NULL

5	NULL
.	NULL

Baldari	NULL
,	NULL
C.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
H.	NULL
Murray	NULL
,	NULL
P.	NULL
Ghiara	NULL
,	NULL
G.	NULL
Cesareni	NULL
,	NULL
and	NULL
C.	NULL
L.	NULL
Galeotti	NULL
1987	NULL
.	NULL

A	NULL
novel	NULL
leader	NULL
peptide	NULL
which	NULL
allows	NULL
efficient	NULL
secretion	NULL
of	NULL
a	NULL
fragment	NULL
of	NULL
human	NULL
interleukin	NULL
18	NULL
in	NULL
Saccharomyces	NULL
cerevisiae	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6229-234	NULL
.	NULL

6	NULL
.	NULL

Barbour	NULL
,	NULL
A.	NULL
G.	NULL
1984	NULL
.	NULL

Isolation	NULL
and	NULL
cultivation	NULL
of	NULL
Lyme	NULL
disease	NULL
spirochetes	NULL
.	NULL

Yale	NULL
J.	NULL
Biol	NULL
.	NULL

Med	NULL
.	NULL

57:521-525	NULL
.	NULL

7	NULL
.	NULL

Belisle	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
M.	NULL
E.	NULL
Brandt	NULL
,	NULL
J.	NULL
D.	NULL
Radolf	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1994	NULL
.	NULL

Fatty	NULL
acids	NULL
of	NULL
Treponema	NULL
pallidum	NULL
and	NULL
Borrelia	NULL
burgdorfen	NULL
lipoproteins	NULL
.	NULL

J.	NULL
Bacteriol	NULL
.	NULL

176:2151-2157	NULL
.	NULL

8	NULL
.	NULL

Bergstrom	NULL
,	NULL
S.	NULL
,	NULL
V.	NULL
G.	NULL
Bundoc	NULL
,	NULL
and	NULL
A.	NULL
G.	NULL
Barbour	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
analysis	NULL
of	NULL
linear	NULL
plasmid-encoded	NULL
major	NULL
surface	NULL
proteins	NULL
,	NULL
OspA	NULL
and	NULL
OspB	NULL
,	NULL
of	NULL
the	NULL
Lyme	NULL
disease	NULL
spirochaete	NULL
Borrelia	NULL
burgdorferi	NULL
.	NULL

Mol	NULL
.	NULL

Microbiol	NULL
.	NULL

3:479-486	NULL
.	NULL

9	NULL
.	NULL

Bessler	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
M.	NULL
Cox	NULL
,	NULL
A.	NULL
Lex	NULL
,	NULL
B.	NULL
Suhr	NULL
,	NULL
K.-H.	NULL
Wiesmuller	NULL
,	NULL
and	NULL
G.	NULL
Jung	NULL
.	NULL

1985	NULL
.	NULL

Synthetic	NULL
lipopeptide	NULL
analogs	NULL
of	NULL
bacterial	NULL
lipoprotein	NULL
are	NULL
potent	NULL
poly-clonal	NULL
activators	NULL
for	NULL
murine	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

135:1900-1905	NULL
.	NULL

10	NULL
.	NULL

Brandt	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
B.	NULL
S.	NULL
Riley	NULL
,	NULL
J.	NULL
D.	NULL
Radolf	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1990	NULL
.	NULL

Immunogenic	NULL
integral	NULL
membrane	NULL
proteins	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
are	NULL
lipoproteins	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

58:983-991	NULL
.	NULL

11	NULL
.	NULL

Chamberlain	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
M.	NULL
E.	NULL
Brandt	NULL
,	NULL
A.	NULL
L.	NULL
Erwin	NULL
,	NULL
J.	NULL
D.	NULL
Radolf	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1989	NULL
.	NULL

Major	NULL
integral	NULL
membrane	NULL
protein	NULL
immunogens	NULL
of	NULL
Treponema	NULL
pallidum	NULL
are	NULL
proteolipids	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

57:2872-2877	NULL
.	NULL

12	NULL
.	NULL

Champion	NULL
,	NULL
C.	NULL
L	NULL
,	NULL
D.	NULL
R.	NULL
Blanco	NULL
,	NULL
J.	NULL
T.	NULL
Skare	NULL
,	NULL
D.	NULL
A.	NULL
Haake	NULL
,	NULL
M.	NULL
Giladi	NULL
,	NULL
D.	NULL
Foley	NULL
,	NULL
J.	NULL
N.	NULL
Miller	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Lovett	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
9.0-kilobase-pair	NULL
circular	NULL
plasmid	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
encodes	NULL
an	NULL
exported	NULL
protein	NULL
:	NULL
evidence	NULL
for	NULL
expression	NULL
only	NULL
during	NULL
infection	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

62:2653-2661	NULL
.	NULL

13	NULL
.	NULL

Corradin	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
J.	NULL
Mauel	NULL
,	NULL
P.	NULL
Gallay	NULL
,	NULL
D.	NULL
Heumann	NULL
,	NULL
R.	NULL
J.	NULL
Ulevitch	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Tobias	NULL
.	NULL

1992	NULL
.	NULL

Enhancement	NULL
of	NULL
murine	NULL
macrophages	NULL
binding	NULL
of	NULL
and	NULL
response	NULL
to	NULL
bacterial	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
by	NULL
LPS-binding	NULL
protein	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

52:363-368	NULL
.	NULL

14	NULL
.	NULL

DeOgny	NULL
,	NULL
L.	NULL
,	NULL
B.	NULL
C.	NULL
Pramanik	NULL
,	NULL
L.	NULL
L.	NULL
Arndt	NULL
,	NULL
J.	NULL
D.	NULL
Jones	NULL
,	NULL
J	NULL
.	NULL

Rush	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

Slaughter	NULL
,	NULL
J.	NULL
D.	NULL
Radolf	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1994	NULL
.	NULL

Solid-phase	NULL
synthesis	NULL
of	NULL
biologically	NULL
active	NULL
lipopeptides	NULL
as	NULL
analogs	NULL
for	NULL
spirochetal	NULL
lipoproteins	NULL
.	NULL

Peptide	NULL
Res	NULL
.	NULL

7:91-97	NULL
.	NULL

15	NULL
.	NULL

Dong	NULL
,	NULL
Z.	NULL
,	NULL
X.	NULL
Qi	NULL
,	NULL
and	NULL
I.	NULL
J.	NULL
Fidler	NULL
.	NULL

1993	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
is	NULL
necessary	NULL
for	NULL
activation	NULL
of	NULL
murine	NULL
macrophages	NULL
by	NULL
natural	NULL
and	NULL
synthetic	NULL
bacterial	NULL
products	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177:1071-1077	NULL
.	NULL

16	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
S.	NULL
M.	NULL
Schnittman	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
S.	NULL
Koenig	NULL
,	NULL
and	NULL
G.	NULL
Pantaleo	NULL
.	NULL

1991	NULL
.	NULL

Immunopathogenic	NULL
mechanisms	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
infection	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

114:678-693	NULL
.	NULL

17	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
J.	NULL
Justement	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
C.	NULL
Dinarello	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1987	NULL
.	NULL

Cytokine-induced	NULL
expression	NULL
of	NULL
HIV-1	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
promono-cyte	NULL
line	NULL
.	NULL

Science	NULL
238:800-802	NULL
.	NULL

18	NULL
.	NULL

Han	NULL
,	NULL
J.	NULL
,	NULL
J.-D.	NULL
Lee	NULL
,	NULL
L.	NULL
Bibbs	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Ulevitch	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
MAP	NULL
kinase	NULL
targeted	NULL
by	NULL
endotoxin	NULL
and	NULL
hyperosmolarity	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Science	NULL
265:808-811	NULL
.	NULL

19	NULL
.	NULL

Han	NULL
,	NULL
J.	NULL
,	NULL
J.-D.	NULL
Lee	NULL
,	NULL
P.	NULL
S.	NULL
Tobias	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Ulevitch	NULL
.	NULL

1993	NULL
.	NULL

Endotoxin	NULL
induces	NULL
rapid	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
70Z/3	NULL
cells	NULL
expressing	NULL
CD14	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:25009-25014	NULL
.	NULL

20	NULL
.	NULL

Hardy	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
J.	NULL
Levin	NULL
.	NULL

1983	NULL
.	NULL

Lack	NULL
of	NULL
endotoxin	NULL
in	NULL
Borrelia	NULL
hispanica	NULL
and	NULL
Treponema	NULL
pallidum	NULL
.	NULL

Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

174:47-52	NULL
.	NULL

21	NULL
.	NULL

Harris	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
P.	NULL
Ralph	NULL
.	NULL

1985	NULL
.	NULL

Human	NULL
leukemic	NULL
models	NULL
of	NULL
myelomonocytic	NULL
development	NULL
:	NULL
a	NULL
review	NULL
of	NULL
the	NULL
HL-60	NULL
and	NULL
U937	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

37:407-422	NULL
.	NULL

22	NULL
.	NULL

Hauschildt	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Hoffmann	NULL
,	NULL
H.	NULL
U.	NULL
Beuscher	NULL
,	NULL
G.	NULL
Dufhues	NULL
,	NULL
P.	NULL
Heinrich	NULL
,	NULL
K.-H.	NULL
Wiesmuller	NULL
,	NULL
G.	NULL
Jung	NULL
,	NULL
and	NULL
W.	NULL
G.	NULL
Bessler	NULL
,	NULL
.	NULL

1990	NULL
.	NULL

Activation	NULL
of	NULL
bone	NULL
marrow-derived	NULL
mouse	NULL
macrophages	NULL
by	NULL
bacterial	NULL
lipopeptide	NULL
:	NULL
cytokine	NULL
production	NULL
,	NULL
phagocytosis	NULL
,	NULL
and	NULL
Ta	NULL
expression	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

20:63-68	NULL
.	NULL

23	NULL
.	NULL

Haziot	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Ferrero	NULL
,	NULL
F.	NULL
Kontgen	NULL
,	NULL
N.	NULL
Hijiya	NULL
,	NULL
S.	NULL
Yamamoto	NULL
,	NULL
J	NULL
.	NULL

Silver	NULL
,	NULL
C.	NULL
L.	NULL
Stewart	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Goyert	NULL
.	NULL

1996	NULL
.	NULL

Resistance	NULL
to	NULL
endotoxin	NULL
shock	NULL
and	NULL
reduced	NULL
dissemination	NULL
of	NULL
gram-negative	NULL
bacteria	NULL
in	NULL
CD14-deficient	NULL
mice	NULL
.	NULL

Immunity	NULL
4:407-414	NULL
.	NULL

3852	NULL
24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

NORGARD	NULL
ET	NULL
AL	NULL
.	NULL

Ho	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
T.	NULL
R.	NULL
Rota	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Hirsch	NULL
.	NULL

1986	NULL
.	NULL

Infection	NULL
of	NULL
monocyte/	NULL
macrophages	NULL
by	NULL
human	NULL
T	NULL
lymphotrophic	NULL
virus	NULL
type	NULL
IIL	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

77:1712-1715	NULL
.	NULL

Hoffmann	NULL
,	NULL
P.	NULL
,	NULL
S.	NULL
Heinle	NULL
,	NULL
U.	NULL
F.	NULL
Schade	NULL
,	NULL
H.	NULL
Loppnow	NULL
,	NULL
A.	NULL
J.	NULL
Ulmer	NULL
,	NULL
H.-D.	NULL
Flad	NULL
,	NULL
G.	NULL
Jung	NULL
,	NULL
and	NULL
W.	NULL
G.	NULL
Bessler	NULL
.	NULL

1988	NULL
.	NULL

Stimulation	NULL
of	NULL
human	NULL
and	NULL
murine	NULL
adherent	NULL
cells	NULL
by	NULL
bacterial	NULL
lipoprotein	NULL
and	NULL
synthetic	NULL
lipopeptide	NULL
analogues	NULL
.	NULL

Immunobiology	NULL
177:158-170	NULL
.	NULL

Hook	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
III	NULL
.	NULL

1989	NULL
.	NULL

Syphilis	NULL
and	NULL
HIV	NULL
infection	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

160:530-534	NULL
.	NULL

Hutchinson	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
A.	NULL
M.	NULL
Rompalo	NULL
,	NULL
C.	NULL
A.	NULL
Reichart	NULL
,	NULL
and	NULL
E.	NULL
W.	NULL
Hook	NULL
.	NULL

1991	NULL
.	NULL

Characteristics	NULL
of	NULL
patients	NULL
with	NULL
syphilis	NULL
attending	NULL
Baltimore	NULL
STD	NULL
clinics	NULL
:	NULL
multiple	NULL
high-risk	NULL
subgroups	NULL
and	NULL
interactions	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Arch	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

151:511-516	NULL
.	NULL

Jeerapaet	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Ackerman	NULL
.	NULL

1973	NULL
.	NULL

Histologic	NULL
patterns	NULL
of	NULL
secondary	NULL
syphilis	NULL
.	NULL

Arch	NULL
.	NULL

Dermatol	NULL
.	NULL

107:373-377	NULL
.	NULL

Jones	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
K.	NULL
W.	NULL
Bourell	NULL
,	NULL
M.	NULL
V.	NULL
Norgard	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Radolf	NULL
.	NULL

1995	NULL
.	NULL

Membrane	NULL
topology	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
and	NULL
Treponema	NULL
pallidum	NULL
lipoproteins	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

63:2424-2434	NULL
.	NULL

Kirkland	NULL
,	NULL
T.	NULL
N.	NULL
,	NULL
G.	NULL
D.	NULL
Virca	NULL
,	NULL
T.	NULL
Kuus	NULL
Reichel	NULL
,	NULL
F.	NULL
K.	NULL
Multer	NULL
,	NULL
S.	NULL
Y.	NULL
Kim	NULL
,	NULL
R.	NULL
J.	NULL
Ulevitch	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Tobias	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
lipopolysaccharide-binding	NULL
proteins	NULL
in	NULL
70Z/3	NULL
cells	NULL
by	NULL
photoaffinity	NULL
cross-linking	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
:	NULL
9520-9525	NULL
.	NULL

Kitchens	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
R.	NULL
J.	NULL
Ulevitch	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Munford	NULL
.	NULL

1992	NULL
.	NULL

Lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
partial	NULL
structures	NULL
inhibit	NULL
responses	NULL
to	NULL
LPS	NULL
in	NULL
a	NULL
human	NULL
macrophage	NULL
cell	NULL
line	NULL
without	NULL
inhibiting	NULL
LPS	NULL
uptake	NULL
by	NULL
a	NULL
CD14-mediated	NULL
pathway	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:485-494	NULL
.	NULL

Kreutz	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
R.	NULL
Andreesen	NULL
.	NULL

1990	NULL
.	NULL

Induction	NULL
of	NULL
human	NULL
monocyte	NULL
to	NULL
macrophage	NULL
maturation	NULL
in	NULL
vitro	NULL
by	NULL
1,25-dibhydroxyvitamin	NULL
D	NULL
;	NULL
.	NULL

Blood	NULL
76	NULL
:	NULL
2457-2461	NULL
.	NULL

Lee	NULL
,	NULL
J.-D.	NULL
,	NULL
K.	NULL
Kato	NULL
,	NULL
P.	NULL
S.	NULL
Tobias	NULL
,	NULL
T.	NULL
N.	NULL
Kirkland	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Ulevitch	NULL
.	NULL

1992	NULL
.	NULL

Transfection	NULL
of	NULL
CD14	NULL
into	NULL
70Z/3	NULL
cells	NULL
dramatically	NULL
enhances	NULL
the	NULL
sensitivity	NULL
to	NULL
complexes	NULL
of	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
and	NULL
LPS	NULL
binding	NULL
protein	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1697-1705	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
:	NULL
a	NULL
pleiotropic	NULL
mediator	NULL
of	NULL
inducible	NULL
and	NULL
tissue-specific	NULL
gene	NULL
control	NULL
.	NULL

Cell	NULL
58:227-229	NULL
.	NULL

Lukehart	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
K.	NULL
Holmes	NULL
.	NULL

1994	NULL
.	NULL

Syphilis	NULL
,	NULL
p.	NULL
726-737	NULL
.	NULL

In	NULL
K.	NULL
J.	NULL
Isselbacher	NULL
,	NULL
E.	NULL
Braunwald	NULL
,	NULL
J.	NULL
Wilson	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Martin	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Kasper	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Harrison	NULL
's	NULL
principles	NULL
of	NULL
internal	NULL
medicine	NULL
.	NULL

McGraw-Hill	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Ma	NULL
,	NULL
Y.	NULL
,	NULL
K.	NULL
P.	NULL
Seiler	NULL
,	NULL
K.-F.	NULL
Tai	NULL
,	NULL
L.	NULL
Yang	NULL
,	NULL
M.	NULL
Woods	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Weis	NULL
.	NULL

1994	NULL
.	NULL

Outer	NULL
surface	NULL
lipoproteins	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
stimulate	NULL
nitric	NULL
oxide	NULL
production	NULL
by	NULL
the	NULL
cytokine-inducible	NULL
pathway	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

62:3663-3671	NULL
.	NULL

Ma	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Weis	NULL
.	NULL

1993	NULL
.	NULL

Borrelia	NULL
burgdorferi	NULL
outer	NULL
surface	NULL
lipoproteins	NULL
OspA	NULL
and	NULL
OspB	NULL
possess	NULL
B-cell	NULL
mitogenic	NULL
and	NULL
cytokine-stimulatory	NULL
proper-tics	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

61:3843-3853	NULL
.	NULL

Marra	NULL
,	NULL
C.	NULL
M.	NULL
1992	NULL
.	NULL

Syphilis	NULL
and	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Semin	NULL
.	NULL

Neurol	NULL
.	NULL

12:43-50	NULL
.	NULL

Metzger	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
W.	NULL
H.	NULL
Sawyer	NULL
,	NULL
B.	NULL
Wille	NULL
,	NULL
L.	NULL
Biesert	NULL
,	NULL
W.	NULL
G.	NULL
Bessler	NULL
,	NULL
and	NULL
G.	NULL
Jung	NULL
.	NULL

1993	NULL
.	NULL

Interaction	NULL
of	NULL
immunologically-active	NULL
lipopeptides	NULL
with	NULL
mem-branes	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1149:29-39	NULL
.	NULL

Montgomery	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
S.	NULL
E.	NULL
Malawista	NULL
,	NULL
K.	NULL
J.	NULL
M.	NULL
Feen	NULL
,	NULL
and	NULL
L.	NULL
K.	NULL
Bockenstedt	NULL
.	NULL

1996	NULL
.	NULL

Direct	NULL
demonstration	NULL
of	NULL
antigenic	NULL
substitution	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
ex	NULL
vivo	NULL
:	NULL
exploration	NULL
of	NULL
the	NULL
paradox	NULL
of	NULL
the	NULL
early	NULL
immune	NULL
response	NULL
to	NULL
outer	NULL
surface	NULL
proteins	NULL
A	NULL
and	NULL
C	NULL
in	NULL
Lyme	NULL
disease	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:261-269	NULL
.	NULL

Muller	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
H.	NULL
W.	NULL
L.	NULL
Ziegler-Heitbrock	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1993	NULL
.	NULL

Nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
,	NULL
a	NULL
mediator	NULL
of	NULL
lipopolysaccharide	NULL
effects	NULL
.	NULL

Immunobiology	NULL
187:233-256	NULL
.	NULL

Nocton	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
A.	NULL
C.	NULL
Steere	NULL
.	NULL

1995	NULL
.	NULL

Lyme	NULL
disease	NULL
.	NULL

Adv	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

40:69-115	NULL
.	NULL

Norgard	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
B.	NULL
S.	NULL
Riley	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Richardson	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Radolf	NULL
.	NULL

1995	NULL
.	NULL

Dermal	NULL
inflammation	NULL
elicited	NULL
by	NULL
synthetic	NULL
analogs	NULL
of	NULL
Treponema	NULL
pallidum	NULL
and	NULL
Borrelia	NULL
burgdorferi	NULL
lipoproteins	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

63:1507-1515	NULL
.	NULL

Offermanns	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Seifert	NULL
,	NULL
J.	NULL
W.	NULL
Metzger	NULL
,	NULL
G.	NULL
Jung	NULL
,	NULL
A.	NULL
Liecberknecht	NULL
,	NULL
U.	NULL
Schmidt	NULL
,	NULL
and	NULL
G.	NULL
Schultz	NULL
.	NULL

1992	NULL
.	NULL

Lipopeptides	NULL
are	NULL
effective	NULL
stimulators	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
human	NULL
myeloid	NULL
cells	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

282:551-557	NULL
.	NULL

Paige	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
P.	NULL
W.	NULL
Kincade	NULL
,	NULL
and	NULL
P.	NULL
Ralph	NULL
.	NULL

1978	NULL
.	NULL

Murine	NULL
B	NULL
cell	NULL
leukemia	NULL
line	NULL
with	NULL
inducible	NULL
surface	NULL
immunoglobulin	NULL
expression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

121:641-647	NULL
.	NULL

Pomerantz	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
M.	NULL
B.	NULL
Feinberg	NULL
,	NULL
D.	NULL
Trono	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Lipopolysaccharide	NULL
is	NULL
a	NULL
potent	NULL
monocyte/macrophage-specific	NULL
stimulator	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
expression	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:253-261	NULL
.	NULL

Pugin	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
Heumann	NULL
,	NULL
A.	NULL
Tomasz	NULL
,	NULL
V.	NULL
V.	NULL
Kravchenko	NULL
,	NULL
Y.	NULL
Akamatsu	NULL
,	NULL
M.	NULL
Nishijima	NULL
,	NULL
M.	NULL
P.	NULL
Glauser	NULL
,	NULL
P.	NULL
S.	NULL
Tobias	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Ulevitch	NULL
.	NULL

1994	NULL
.	NULL

CD14	NULL
is	NULL
a	NULL
pattern	NULL
recognition	NULL
receptor	NULL
.	NULL

Immunity	NULL
1:509-516	NULL
.	NULL

Radolf	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
K.	NULL
W.	NULL
Bourell	NULL
,	NULL
D.	NULL
R.	NULL
Akins	NULL
,	NULL
J.	NULL
S.	NULL
Brusca	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1994	NULL
.	NULL

Analysis	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
membrane	NULL
architecture	NULL
by	NULL
freeze-frac-ture	NULL
electron	NULL
microscopy	NULL
.	NULL

J.	NULL
Bacteriol	NULL
.	NULL

176:21-31	NULL
.	NULL

Radolf	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1988	NULL
.	NULL

Pathogen-specificity	NULL
of	NULL
integral	NULL
Editor	NULL
:	NULL
R.	NULL
E.	NULL
McCallum	NULL
50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

InFECT	NULL
.	NULL

ImnmUN	NULL
.	NULL

membrane	NULL
proteins	NULL
of	NULL
Treponema	NULL
pallidum	NULL
subsp	NULL
.	NULL

pallidum	NULL
identified	NULL
by	NULL
phase	NULL
partitioning	NULL
with	NULL
Triton	NULL
X-114	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

56:1825-1828	NULL
.	NULL

Radolf	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
M.	NULL
V.	NULL
Norgard	NULL
,	NULL
M.	NULL
E.	NULL
Brandt	NULL
,	NULL
R.	NULL
D.	NULL
Isaacs	NULL
,	NULL
P.	NULL
A.	NULL
Thompson	NULL
,	NULL
and	NULL
B.	NULL
Beutler	NULL
.	NULL

1991	NULL
.	NULL

Lipoproteins	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
and	NULL
Treponema	NULL
pallidum	NULL
activate	NULL
cachectin/tumor	NULL
necrosis	NULL
factor	NULL
synthesis	NULL
:	NULL
analysis	NULL
using	NULL
a	NULL
CAT	NULL
reporter	NULL
construct	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:1968-1974	NULL
.	NULL

Radolf	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
L.	NULL
L.	NULL
Arndt	NULL
,	NULL
D.	NULL
R.	NULL
Akins	NULL
,	NULL
L.	NULL
L.	NULL
Curetty	NULL
,	NULL
M.	NULL
E.	NULL
Levi	NULL
,	NULL
Y.	NULL
Shen	NULL
,	NULL
L.	NULL
S.	NULL
Davis	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1995	NULL
.	NULL

Treponema	NULL
pallidum	NULL
and	NULL
Borrelia	NULL
burgdorferi	NULL
lipoproteins	NULL
and	NULL
synthetic	NULL
lipopeptides	NULL
activate	NULL
monocytes/mac-rophages	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:2866-2877	NULL
.	NULL

Rawadi	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
S.	NULL
Roman-Roman	NULL
.	NULL

1996	NULL
.	NULL

Mycoplasma	NULL
membrane	NULL
lipoproteins	NULL
induce	NULL
proinflammatory	NULL
cytokines	NULL
by	NULL
a	NULL
mechanism	NULL
distinct	NULL
from	NULL
that	NULL
of	NULL
lipopolysaccharide	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

64:637-643	NULL
.	NULL

Riley	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
N.	NULL
Oppenheimer-Marks	NULL
,	NULL
E.	NULL
J.	NULL
Hansen	NULL
,	NULL
J.	NULL
D.	NULL
Radolf	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1992	NULL
.	NULL

Virulent	NULL
Treponema	NULL
pallidum	NULL
activates	NULL
human	NULL
vascular	NULL
endothelial	NULL
cells	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

165:484-493	NULL
.	NULL

Roulston	NULL
,	NULL
A.	NULL
,	NULL
R.	NULL
Lin	NULL
,	NULL
P.	NULL
Beauparlant	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
and	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
myeloid	NULL
cells	NULL
by	NULL
NF-	NULL
«	NULL
B/Rel	NULL
transcription	NULL
factors	NULL
.	NULL

Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

59:481-505	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Schouls	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
R.	NULL
Mout	NULL
,	NULL
J.	NULL
Dekker	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
A	NULL
.	NULL

Van	NULL
Embden	NULL
.	NULL

1989	NULL
.	NULL

Characterization	NULL
of	NULL
lipid-modified	NULL
immunogenic	NULL
proteins	NULL
of	NULL
Treponeme	NULL
pallidum	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
.	NULL

Microb	NULL
.	NULL

Pathog	NULL
.	NULL

7:175-188	NULL
.	NULL

Schwan	NULL
,	NULL
T.	NULL
G.	NULL
,	NULL
J.	NULL
Piesman	NULL
,	NULL
W.	NULL
T.	NULL
Golde	NULL
,	NULL
M.	NULL
C.	NULL
Dolan	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Rosa	NULL
.	NULL

1995	NULL
.	NULL

Induction	NULL
of	NULL
an	NULL
outer	NULL
surface	NULL
protein	NULL
on	NULL
Borrelia	NULL
burgdorferi	NULL
during	NULL
tick	NULL
feeding	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:2909-2913	NULL
.	NULL

Sellati	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
L.	NULL
D.	NULL
Abrescia	NULL
,	NULL
J.	NULL
D.	NULL
Radolf	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Furie	NULL
.	NULL

1996	NULL
.	NULL

Outer	NULL
surface	NULL
lipoproteins	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
activate	NULL
vascular	NULL
endothelium	NULL
in	NULL
vitro	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

64:3180-3187	NULL
.	NULL

Sibley	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
A.	NULL
Terry	NULL
,	NULL
and	NULL
C.	NULL
R.	NULL
H.	NULL
Raetz	NULL
.	NULL

1988	NULL
.	NULL

Induction	NULL
of	NULL
kappa	NULL
light	NULL
chain	NULL
synthesis	NULL
in	NULL
70Z/3	NULL
B	NULL
lymphoma	NULL
cells	NULL
by	NULL
chemically	NULL
defined	NULL
lipid	NULL
A	NULL
precursors	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:5098-5103	NULL
.	NULL

Smith	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
and	NULL
K.	NULL
S.	NULL
Johnson	NULL
.	NULL

1988	NULL
.	NULL

Single-step	NULL
purification	NULL
of	NULL
polypep-tides	NULL
expressed	NULL
in	NULL
Escherichia	NULL
colt	NULL
as	NULL
fusions	NULL
with	NULL
glutathione	NULL
S-transferase	NULL
.	NULL

Gene	NULL
67:31-40	NULL
.	NULL

Stamm	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
H.	NULL
H.	NULL
Handsfield	NULL
,	NULL
A.	NULL
M.	NULL
Rompalo	NULL
,	NULL
R.	NULL
L.	NULL
Ashley	NULL
,	NULL
P.	NULL
L.	NULL
Roberts	NULL
,	NULL
and	NULL
L.	NULL
Corey	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
association	NULL
between	NULL
genital	NULL
ulcer	NULL
disease	NULL
and	NULL
acquisition	NULL
of	NULL
HIV	NULL
infection	NULL
in	NULL
homosexual	NULL
men	NULL
.	NULL

JAMA	NULL
260:1429-1433	NULL
.	NULL

Stevenson	NULL
,	NULL
B.	NULL
,	NULL
T.	NULL
G.	NULL
Schwan	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Rosa	NULL
.	NULL

1995	NULL
.	NULL

Temperature-related	NULL
differential	NULL
expression	NULL
of	NULL
antigens	NULL
in	NULL
the	NULL
Lyme	NULL
disease	NULL
spirochete	NULL
,	NULL
Borrelia	NULL
burgdorferi	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

63:4535-4539	NULL
.	NULL

Tai	NULL
,	NULL
K.-F.	NULL
,	NULL
Y.	NULL
Ma	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Weis	NULL
.	NULL

1994	NULL
.	NULL

Normal	NULL
human	NULL
B	NULL
lymphocytes	NULL
and	NULL
mononuclear	NULL
cells	NULL
respond	NULL
to	NULL
the	NULL
mitogenic	NULL
and	NULL
cytokine-stimulatory	NULL
activities	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
and	NULL
its	NULL
lipoprotein	NULL
OspA	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

62:520-528	NULL
.	NULL

Takayama	NULL
,	NULL
K.	NULL
,	NULL
R.	NULL
J.	NULL
Rothenberg	NULL
,	NULL
and	NULL
A.	NULL
G.	NULL
Barbour	NULL
.	NULL

1987	NULL
.	NULL

Absence	NULL
of	NULL
lipopolysaccharide	NULL
in	NULL
the	NULL
Lyme	NULL
disease	NULL
spirochete	NULL
,	NULL
Borrelia	NULL
burgdorferi	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

55:2311-2313	NULL
.	NULL

Tatro	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
L.	NULL
I.	NULL
Romero	NULL
,	NULL
D.	NULL
Beasley	NULL
,	NULL
A.	NULL
C.	NULL
Steere	NULL
,	NULL
and	NULL
S.	NULL
Reichlin	NULL
.	NULL

1994	NULL
.	NULL

Borrelia	NULL
burgdorferi	NULL
and	NULL
Escherichia	NULL
coli	NULL
lipopolysaccharides	NULL
induce	NULL
nitric	NULL
oxide	NULL
and	NULL
interleukin-6	NULL
production	NULL
in	NULL
cultured	NULL
rat	NULL
brain	NULL
cells	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

169:1014-1022	NULL
.	NULL

Tsuchiya	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Yamabe	NULL
,	NULL
Y.	NULL
Yamaguchi	NULL
,	NULL
Y.	NULL
Kobayashi	NULL
,	NULL
T.	NULL
Konno	NULL
,	NULL
and	NULL
K.	NULL
Tada	NULL
.	NULL

1980	NULL
.	NULL

Establishment	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
human	NULL
acute	NULL
monocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
THP-1	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
26:171-176	NULL
.	NULL

Ulevitch	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Tobias	NULL
.	NULL

1995	NULL
.	NULL

Receptor-dependent	NULL
mechanisms	NULL
of	NULL
cell	NULL
stimulation	NULL
by	NULL
bacterial	NULL
endotoxin	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

13:437-457	NULL
.	NULL

Wallach	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
Brenner	NULL
,	NULL
M.	NULL
D.	NULL
Kramer	NULL
,	NULL
and	NULL
M.	NULL
M.	NULL
Simon	NULL
.	NULL

1995	NULL
.	NULL

Molecular	NULL
cloning	NULL
and	NULL
immunological	NULL
characterization	NULL
of	NULL
a	NULL
novel	NULL
lincar-plasmid-en-coded	NULL
gene	NULL
,	NULL
pG	NULL
,	NULL
of	NULL
Borrelia	NULL
burgdorferi	NULL
expressed	NULL
only	NULL
in	NULL
vivo	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

63:3327-3335	NULL
.	NULL

Wasserheit	NULL
,	NULL
J.	NULL
N.	NULL
1992	NULL
.	NULL

Epidemiological	NULL
synergy	NULL
.	NULL

Interrelationships	NULL
between	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
and	NULL
other	NULL
sexually	NULL
transmitted	NULL
dis-cases	NULL
.	NULL

Sex	NULL
.	NULL

Transm	NULL
.	NULL

Dis	NULL
.	NULL

19:61-77	NULL
.	NULL

Weigel	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
M.	NULL
E.	NULL
Brandt	NULL
,	NULL
and	NULL
M.	NULL
V.	NULL
Norgard	NULL
.	NULL

1992	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
N-terminal	NULL
region	NULL
of	NULL
the	NULL
47-kilodalton	NULL
integral	NULL
membrane	NULL
lipoprotein	NULL
of	NULL
Treponema	NULL
pallidum	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

60:1568-1576	NULL
.	NULL

Weis	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Y.	NULL
Ma	NULL
,	NULL
and	NULL
L.	NULL
F.	NULL
Erdile	NULL
.	NULL

1994	NULL
.	NULL

Biological	NULL
activities	NULL
of	NULL
native	NULL
and	NULL
recombinant	NULL
Borrelia	NULL
burgdorferi	NULL
outer	NULL
surface	NULL
protein	NULL
A	NULL
:	NULL
dependence	NULL
on	NULL
lipid	NULL
modification	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

62:4632-4636	NULL
.	NULL

Yun	NULL
Tso	NULL
,	NULL
J.	NULL
,	NULL
X.-H.	NULL
Sun	NULL
,	NULL
T.	NULL
Kao	NULL
,	NULL
K.	NULL
S.	NULL
Reece	NULL
,	NULL
and	NULL
R.	NULL
Wu	NULL
.	NULL

1985	NULL
.	NULL

Isolation	NULL
and	NULL
characterization	NULL
of	NULL
rat	NULL
and	NULL
human	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
cDNAs	NULL
:	NULL
genomic	NULL
complexity	NULL
and	NULL
molecular	NULL
evolution	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

13:2485-2502	NULL
.	NULL

